<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">66657</article-id><article-id pub-id-type="doi">10.7554/eLife.66657</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group></article-categories><title-group><article-title>Structure-guided microbial targeting of antistaphylococcal prodrugs</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-223843"><name><surname>Miller</surname><given-names>Justin J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9400-8916</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-223844"><name><surname>Shah</surname><given-names>Ishaan T</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-223845"><name><surname>Hatten</surname><given-names>Jayda</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-223846"><name><surname>Barekatain</surname><given-names>Yasaman</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-223847"><name><surname>Mueller</surname><given-names>Elizabeth A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-5482-6551</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-223848"><name><surname>Moustafa</surname><given-names>Ahmed M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-9949-6936</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-223849"><name><surname>Edwards</surname><given-names>Rachel L</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-223850"><name><surname>Dowd</surname><given-names>Cynthia S</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-95662"><name><surname>Planet</surname><given-names>Paul J</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-223851"><name><surname>Muller</surname><given-names>Florian L</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-134544"><name><surname>Jez</surname><given-names>Joseph M</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-89483"><name><surname>Odom John</surname><given-names>Audrey R</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8395-8537</contrib-id><email>johna3@email.chop.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Department of Pediatrics, Washington University School of Medicine</institution><addr-line><named-content content-type="city">St. Louis</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Department of Biology, Washington University in St. Louis</institution><addr-line><named-content content-type="city">St. Louis</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Children’s Hospital of Philadelphia</institution><addr-line><named-content content-type="city">Philadelphia</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution>Department of Chemistry, The George Washington University</institution><addr-line><named-content content-type="city">Washington</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution>Department of Molecular Microbiology, Washington University School of Medicine</institution><addr-line><named-content content-type="city">St. Louis</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Kana</surname><given-names>Bavesh D</given-names></name><role>Reviewing Editor</role><aff><institution>University of the Witwatersrand</institution><country>South Africa</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Kana</surname><given-names>Bavesh D</given-names></name><role>Senior Editor</role><aff><institution>University of the Witwatersrand</institution><country>South Africa</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>19</day><month>07</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e66657</elocation-id><history><date date-type="received" iso-8601-date="2021-01-18"><day>18</day><month>01</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-07-16"><day>16</day><month>07</month><year>2021</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2020-12-15"><day>15</day><month>12</month><year>2020</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2020.12.15.408237"/></event></pub-history><permissions><copyright-statement>© 2021, Miller et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Miller et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-66657-v2.pdf"/><abstract><p>Carboxy ester prodrugs are widely employed to increase oral absorption and potency of phosphonate antibiotics. Prodrugging can mask problematic chemical features that prevent cellular uptake and may enable tissue-specific compound delivery. However, many carboxy ester promoieties are rapidly hydrolyzed by serum esterases, limiting their therapeutic potential. While carboxy ester-based prodrug targeting is feasible, it has seen limited use in microbes as microbial esterase-specific promoieties have not been described. Here we identify the bacterial esterases, GloB and FrmB, that activate carboxy ester prodrugs in <italic>Staphylococcus aureus.</italic> Additionally, we determine the substrate specificities for FrmB and GloB and demonstrate the structural basis of these preferences. Finally, we establish the carboxy ester substrate specificities of human and mouse sera, ultimately identifying several promoieties likely to be serum esterase-resistant and microbially labile. These studies will enable structure-guided design of antistaphylococcal promoieties and expand the range of molecules to target staphylococcal pathogens.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd><italic>Staphylococcus aureus</italic></kwd><kwd>antibacterial</kwd><kwd>prodrug</kwd><kwd>drug discovery</kwd><kwd>esterase</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Other</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01 AI103280</award-id><principal-award-recipient><name><surname>Odom John</surname><given-names>Audrey R</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R21 AI123808</award-id><principal-award-recipient><name><surname>Odom John</surname><given-names>Audrey R</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R21 AI130584</award-id><principal-award-recipient><name><surname>Odom John</surname><given-names>Audrey R</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000097</institution-id><institution>National Center for Research Resources</institution></institution-wrap></funding-source><award-id>UL1 RR024992</award-id><principal-award-recipient><name><surname>Jez</surname><given-names>Joseph M</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000861</institution-id><institution>Burroughs Wellcome Fund</institution></institution-wrap></funding-source><award-id>PATH</award-id><principal-award-recipient><name><surname>Odom John</surname><given-names>Audrey R</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Prodrug antibiotics can be designed that are serum-stable but readily cleaved inside bacterial pathogens.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Antimicrobial resistance presents a major challenge to public health (<xref ref-type="bibr" rid="bib24">Hsu, 2020</xref>; <xref ref-type="bibr" rid="bib3">Antimicrobial resistance in the age of COVID-19, 2020</xref>). In 2019, 2.8 million antibiotic-resistant infections occurred in the United States, resulting in 35,000 deaths (<xref ref-type="bibr" rid="bib6">CDC, 2019</xref>). Some estimates have suggested that antimicrobial-resistant infections will cause as many as 10 million deaths annually by 2050 (<xref ref-type="bibr" rid="bib57">WHO (World Health Organisation), 2019a</xref>). <italic>Staphylococcus aureus</italic> is a devastating human pathogen. Methicillin-resistant <italic>S. aureus</italic> (MRSA) has been labeled a ‘serious threat’ by the Centers for Disease Control and Prevention (<xref ref-type="bibr" rid="bib6">CDC, 2019</xref>; <xref ref-type="bibr" rid="bib28">Kourtis et al., 2019</xref>; <xref ref-type="bibr" rid="bib51">Turner et al., 2019</xref>). New antimicrobials, especially those with novel mechanisms of action, are urgently needed; however, most anti-infectives under development take advantage of existing antibiotic scaffolds with proven efficacy and established safety profiles (<xref ref-type="bibr" rid="bib18">Global Antimicrobial Resistance Hub, 2020</xref>; <xref ref-type="bibr" rid="bib58">WHO (World Health Organisation), 2019b</xref>). New, chemically distinct antibiotics are highly desirable as a strategy to circumvent antimicrobial resistance.</p><p>Many metabolic processes are essential for microbial growth and/or pathogenesis, although few existing antimicrobials exploit metabolism as an anti-infective target. Metabolic drug design can be facile, as natural substrates serve as a template for competitive inhibitors. As metabolism often involves the transformation of highly charged and polar metabolites, inhibitors of metabolic enzymes often take advantage of phosphonate functional groups for target engagement (<xref ref-type="bibr" rid="bib4">Azema et al., 2006</xref>). Unfortunately, negatively charged phosphonates are readily excluded from cell membranes and often exhibit poor drug-like properties (<xref ref-type="bibr" rid="bib10">Edwards et al., 2020</xref>; <xref ref-type="bibr" rid="bib20">Hecker and Erion, 2008</xref>; <xref ref-type="bibr" rid="bib21">Heidel and Dowd, 2019</xref>; <xref ref-type="bibr" rid="bib23">Hsiao et al., 2014</xref>; <xref ref-type="bibr" rid="bib27">Kornberg et al., 1972</xref>; <xref ref-type="bibr" rid="bib34">Lin et al., 2020</xref>; <xref ref-type="bibr" rid="bib35">Mackie et al., 2012</xref>; <xref ref-type="bibr" rid="bib39">McKenney et al., 2012</xref>; <xref ref-type="bibr" rid="bib59">Wiemer and Wiemer, 2015</xref>; <xref ref-type="bibr" rid="bib64">Zhang et al., 2006</xref>). New strategies enabling effective deployment of antimetabolites will serve to expand the druggable space for antimicrobials.</p><p>One means of improving phosphonate cellular permeability is to chemically mask the undesirable negative charge with lipophilic groups. This strategy (termed prodrugging) can employ labile promoieties that are removed during absorption, distribution, or intracellularly to yield the original phosphonate antibiotic (<xref ref-type="fig" rid="fig1">Figure 1A</xref>; <xref ref-type="bibr" rid="bib20">Hecker and Erion, 2008</xref>; <xref ref-type="bibr" rid="bib21">Heidel and Dowd, 2019</xref>; <xref ref-type="bibr" rid="bib59">Wiemer and Wiemer, 2015</xref>). We have previously designed a series of MEPicide antibiotics, in which phosphonate isoprenoid biosynthesis inhibitors are modified with a lipophilic pivaloyloxymethyl (POM) promoiety. MEPicide prodrugs bypass the need for active cellular transport, while simultaneously increasing compound potency against zoonotic staphylococci, <italic>S. schleiferi</italic> and <italic>S. pseudintermedius</italic>, as well as <italic>Plasmodium falciparum</italic> and <italic>Mycobacterium tuberculosis</italic> (<xref ref-type="bibr" rid="bib10">Edwards et al., 2020</xref>; <xref ref-type="bibr" rid="bib9">Edwards et al., 2017</xref>; <xref ref-type="bibr" rid="bib39">McKenney et al., 2012</xref>; <xref ref-type="bibr" rid="bib48">San Jose et al., 2016</xref>; <xref ref-type="bibr" rid="bib47">San Jose et al., 2013</xref>; <xref ref-type="bibr" rid="bib52">Uh et al., 2011</xref>). However, POM promoieties are rapidly hydrolyzed by serum carboxylesterases, which limits the in vivo efficacy of POM prodrugs as a strategy to improve the drug-like features of charged antimicrobials (<xref ref-type="bibr" rid="bib34">Lin et al., 2020</xref>; <xref ref-type="bibr" rid="bib54">Wang et al., 2018</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Prodrug activation model (<bold>A</bold>) and proposed enzymatic mechanism.</title><p>(<bold>B</bold>) Carboxy ester promoieties highlighted in green.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66657-fig1-v2.tif"/></fig><p>To enable effective cellular delivery of phosphonate antibiotics, new lipophilic prodrug moieties that are resistant to serum carboxylesterases – yet cleavable by microbial esterases – are required. This strategy has been effectively used to achieve tissue-specific selective prodrug activation. For example, liver-targeted prodrug delivery was achieved by harnessing the distinct substrate specificity of the liver-specific isoform of P450, CYP3A4 (<xref ref-type="bibr" rid="bib13">Erion et al., 2005</xref>; <xref ref-type="bibr" rid="bib12">Erion et al., 2004</xref>). Accordingly, understanding the enzymatic and structural mechanisms of microbial prodrug activation will facilitate the development of microbe-specific prodrugs.</p><p>We recently described the staphylococcal enzyme, GloB, which facilitates activation of carboxy ester prodrugs in <italic>S. schleiferi</italic> and <italic>S. pseudintermedius</italic> (<xref ref-type="bibr" rid="bib41">Mikati et al., 2020</xref>). Notably, GloB is insufficient to fully activate prodrugs in vitro, suggesting that at least one additional enzyme is necessary for complete phosphonate release. In this work, we identify and characterize the role of two <italic>S. aureus</italic> esterases, GloB and FrmB, which each catalyze carboxy ester prodrug hydrolysis and contribute to carboxy ester prodrug activation. We demonstrate that both esterases have defined substrate specificities, which diverge from the substrate specificities of human and mouse sera. Finally, we present the three-dimensional structures of GloB and FrmB to enable ongoing structure-guided design of FrmB- and GloB-targeted prodrugs.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Identification of microbial esterases responsible for carboxylesterase activity</title><p>In the zoonotic staphylococcal species <italic>S. schleiferi</italic> and <italic>S. pseudintermedius</italic>, loss of the enzyme GloB, a hydroxyacylglutathione hydrolase, or glyoxalase II enzyme confers resistance to carboxy ester prodrugs because carboxy ester prodrugs are not activated (<xref ref-type="bibr" rid="bib41">Mikati et al., 2020</xref>). However, purified GloB alone is insufficient to activate carboxy ester prodrugs in vitro, suggesting that at least one additional cellular enzyme is required. Based on the hypothesized carboxy ester activation pathway, we predicted that the missing enzyme(s) might be either another carboxylesterase or a phosphodiesterase (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). To establish the pathway for carboxy ester prodrug activation in <italic>S. aureus</italic>, we made use of the Nebraska Transposon Mutant Library (NTML), in which nearly 2000 non-essential <italic>S. aureus</italic> genes have been individually disrupted by a stable transposon insertion (<xref ref-type="bibr" rid="bib16">Fey et al., 2013</xref>). Using the gene ontology feature on the NTML website (<ext-link ext-link-type="uri" xlink:href="https://app1.unmc.edu/fgx/gene-ontologies.html">https://app1.unmc.edu/fgx/gene-ontologies.html</ext-link>), we identified 6 carboxylic ester hydrolases (including <italic>gloB</italic>), 11 phosphatases, and 9 phosphoric diester hydrolases as candidate activators of carboxy ester prodrugs (<xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>). Each identified transposon mutant was screened for resistance to the carboxy ester prodrug, POM-HEX. POM-HEX is a pivaloyloxymethyl prodrug of the compound HEX, which inhibits the glycolytic enzyme enolase (<xref ref-type="fig" rid="fig1">Figures 1B</xref> and <xref ref-type="fig" rid="fig2">Figure 2A</xref>). Of the 26 candidate esterase transposon mutants, only two strains were significantly more resistant to POM-HEX than the <italic>S. aureus</italic> parental strain, JE2, as determined by half-maximal growth inhibitory concentration (IC<sub>50</sub>) (<xref ref-type="fig" rid="fig2">Figure 2B</xref>, <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>). One of these strains had a transposon disrupting the gene that encodes the glyoxalase II enzyme, GloB. The GloB ortholog in <italic>S. scheiferi</italic> is a prodrug-activating enzyme, mutation in which confers resistance to POM-HEX (<xref ref-type="bibr" rid="bib41">Mikati et al., 2020</xref>). The second POM-HEX-resistant strain harbored a transposon insertion in the locus encoding the predicted carboxylesterase annotated as FrmB. FrmB has been previously identified as FphF, a serine hydrolase, and is the primary <italic>S. aureus</italic> target of the sulfonyl fluoride compound JCP678 (<xref ref-type="bibr" rid="bib30">Lentz et al., 2018</xref>). As <italic>S</italic>-formylglutathione hydrolase activity is more likely the biological function of this protein, we will refer to this protein as it has been named in <italic>E. coli</italic>, FrmB.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Forward and reverse genetics approaches identify FrmB and GloB as candidate POM-prodrug hydrolases in <italic>S. aureus</italic>.</title><p>(<bold>A</bold>) Reverse genetics identification of candidate prodrug activating enzymes. (<bold>B</bold>) POM-HEX susceptibility of identified candidate resistance genes from (<bold>A</bold>) as determined by IC<sub>50</sub>. Exact values and error reported in <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>. (<bold>C</bold>) Forward genetic screen approach, all mutations listed in <xref ref-type="supplementary-material" rid="fig2sdata2">Figure 2—source data 2</xref>. (<bold>D</bold>) POM-HEX susceptibility of POM-HEX-resistant <italic>S. aureus</italic>. (<bold>E</bold>) Nonsynonymous point mutations identified by whole-genome sequencing in <italic>frmB</italic> and <italic>gloB</italic>. In all experiments, GloB is colored green and FrmB orange. Displayed are the means of three independent biological experiments.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title><italic>S. aureus</italic> transposon mutants tested and POM-HEX sensitivity.</title><p>Half-maximal inhibitory concentration (IC<sub>50</sub>) values for POM-HEX against predicted prodrug activating esterases. IC<sub>50</sub> values are the result of three independent biological experiments with technical duplicates. p-values calculated as a one-way ANOVA with Dunnett’s correction for multiple comparisons.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-66657-fig2-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title><italic>S. aureus</italic> Newman resistant isolate SNPs and POM-HEX sensitivity.</title><p>Genotype and phenotype of POM-HEX resistant <italic>S. aureus</italic>. Displayed are the whole-genome sequencing mutations that have been verified. Called mutations that were not observed via confirmatory Sanger sequencing are excluded. IC<sub>50</sub> values are the result of three independent biologic replicates with technical duplicates.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-66657-fig2-data2-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig2sdata3"><label>Figure 2—source data 3.</label><caption><title><italic>S. aureus</italic> transposon mutants with genes identified by whole-genome sequencing and POM-HEX sensitivity.</title><p>Half-maximal inhibitory concentration (IC<sub>50</sub>) values for POM-HEX against transposon mutations in genes identified by whole-genome sequencing. Assays performed in biological triplicate with technical duplicates. p-value calculated as a one-way ANOVA with Dunnett correction for multiple comparisons.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-66657-fig2-data3-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig2sdata4"><label>Figure 2—source data 4.</label><caption><title>Accession numbers for the isolates used in WhatsGNU analysis.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-66657-fig2-data4-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66657-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Conservation of FrmB and GloB within <italic>S. aureus</italic>.</title><p>(<bold>A</bold>) WhatsGNU analysis of GloB and FrmB. Control proteins: ArgG, argininosuccinate synthase; Fba, fructose-bisphosphate aldolase; MenD, 2-succinyl-5-enolpyruvyl-6-hydroxy-3-cyclohexene-1carboxylate synthase; and MenC, o-succinylbenzoate synthase. GNU stands for gene novelty unit and is a count of how many protein sequences in the database have an exact match to the queried sequence, with higher counts indicating sequence conservation. Strains across the x-axis are representative strains from the 18 <italic>s. aureus</italic> colony complexes which were used to query the <italic>S. aureus</italic> database. (<bold>B, C</bold>) MAFFT alignment of GloB (<bold>B</bold>) and FrmB (<bold>C</bold>) protein sequences across the <italic>S. aureus</italic> sequence database.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66657-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Phylogenetic tree of FrmB and GloB.</title><p>Sequences of GloB, FrmB, and RpoB (encoding the beta subunit of RNA polymerase, included for comparison) were retrieved from NCBI using BlastP against each organism. Sequence alignment performed using MUSCLE and alignment visualized using the interactive Tree of Life (iTOL).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66657-fig2-figsupp2-v2.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>Enzymatic characterization of GloB and FrmB.</title><p>(<bold>A</bold>) SDS–PAGE gel of GloB and FrmB protein preparations. Expected molecular weights are 23.3 kDa and 29.5 kDa, respectively. (<bold>B</bold>) Glyoxalase II activity assay, enzymatic conversion of S-lactoylglutathione releases free glutathione and reacts with DTNB resulting in increased absorbance at 412 nm. (<bold>C</bold>) 4-Nitrophenyl activation results in increased absorbance at 405 nm. Left to right, activity when supplied 4-nitrophenyl acetate, 4-nitrophenyl butyrate, and 4-nitrophenyl trimethyl acetate. Displayed in points is the mean of two technical replicates for individual experiments, bars indicate mean ± SD of three independent biological experiments performed in technical duplicate.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66657-fig2-figsupp3-v2.tif"/></fig><fig id="fig2s4" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 4.</label><caption><title>NMR characterization of POM-HEX activation by GloB and FrmB.</title><p>Two-dimensional (2D) <sup>1</sup>H-<sup>31</sup>P HSQC NMR spectra of products following incubation of FrmB, GloB, catalytically inactive (boiled) GloB and FrmB, or buffer alone. Also included are the <sup>1</sup>H-<sup>31</sup>P HSQC NMR spectra of POM-HEX and HEX. Displayed are representative traces of three independent experiments. HEMI-POM HEX peak inferred by predicted shift.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66657-fig2-figsupp4-v2.tif"/></fig></fig-group><p>In parallel, we employed an unbiased forward genetics approach to identify genetic changes associated with POM-HEX resistance. POM-HEX-resistant staphylococci were derived by exposing wild-type (WT) <italic>S. aureus</italic> Newman to growth inhibitory concentrations (IC) of POM-HEX. In total, we selected and cloned 25 isolates with IC<sub>50</sub> values ranging from 1.5× to 16× that of WT <italic>S. aureus</italic> Newman (<xref ref-type="fig" rid="fig2">Figure 2C,D</xref>, <xref ref-type="supplementary-material" rid="fig2sdata2">Figure 2—source data 2</xref>).</p><p>Whole-genome sequencing of POM-HEX-resistant strains revealed mutations in <italic>frmB</italic> (n = 7), <italic>gloB</italic> (n = 10), and strains with no mutations in either <italic>frmB</italic> or <italic>gloB</italic> (n = 8). Most mutations were nonsynonymous single-nucleotide polymorphisms (SNPs) (<xref ref-type="fig" rid="fig2">Figure 2D</xref>, <xref ref-type="supplementary-material" rid="fig2sdata2">Figure 2—source data 2</xref>). In three instances, <italic>gloB</italic> was the only verified genetic change in the genome. Additionally, <italic>frmB</italic> and <italic>gloB</italic> each had one instance of a mutation resulting in a premature stop codon truncating the protein to less than a 100 amino acid sequence. Strains with no identified mutations in either <italic>frmB</italic> or <italic>gloB</italic> did not have any mutations, which are immediately obvious as POM-HEX resistance mechanisms. Of the non-<italic>frmB</italic> and non-<italic>gloB</italic> mutations, we selected transposon mutants from the NTML that had transposon insertions in the corresponding genes. These transposon mutations did not confer resistance to POM-HEX (<xref ref-type="supplementary-material" rid="fig2sdata3">Figure 2—source data 3</xref>). Overwhelmingly, the observed mutations in both <italic>frmB</italic> and <italic>gloB</italic> are predicted to have deleterious effects on protein function (PROVEAN score below a threshold of −2.5) (<xref ref-type="fig" rid="fig2">Figure 2E</xref>).</p><p>To evaluate the sequence conservation of FrmB and GloB among <italic>S. aureus</italic>, we performed a WhatsGNU analysis on all publicly available <italic>S. aureus</italic> genomes. WhatsGNU is a bioinformatic tool that can compress large databases and assess the number of instances in which a specific gene has 100% sequence coverage and identity match within the entire database (<xref ref-type="bibr" rid="bib44">Moustafa and Planet, 2020</xref>). This parameter, the gene novelty unit (GNU) score, is high when a sequence is under strong selective pressure within the population and low when the gene is variable. GloB exhibits an exceptionally high GNU score of 8215 (of 10,350 possible), indicating that there is strong sequence conservation for <italic>S. aureus</italic> GloB. Conversely, FrmB sequences appear to be extremely conserved within individual <italic>S. aureus</italic> clonal complexes but varied between each complex (GNU scores of 2218 or 3370 of 10,350, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). We constructed a phylogenetic tree of GloB and FrmB orthologs among microbial populations. Most bacterial species contain a GloB ortholog, though the primary sequence is highly variable across species and does not readily cluster according to the tree of life, as represented by the RNA polymerase RpoB (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). FrmB sequences are also highly sequence divergent, though they tend to cluster closer to the expected tree of life (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>).</p><p>As new antibiotics are introduced, it is important to understand the potential for spontaneous resistance, as this can inform whether co-treatments may be required to circumvent resistance. We determined the resistance frequency for <italic>S. aureus</italic> Newman to POM-HEX as well as several clinically relevant antibiotics. Resistance frequencies were determined at 4 and 10 times the minimum inhibitory concentration (MIC) for each antibiotic in isolation. Spontaneous resistance readily developed during monotreatment with the DNA-dependent RNA synthesis inhibitor, rifampicin, which was used as a comparator (<xref ref-type="bibr" rid="bib45">O'Neill et al., 2001</xref>). We find that spontaneous resistance to rifampicin occurs with frequencies of ~8E-8. Spontaneous resistance was not observed to the cell wall inhibitors nafcillin or vancomycin, nor in the protein synthesis inhibitors linezolid and clindamycin suggesting resistance frequencies of &lt;1 E-11. Spontaneous resistance to POM-HEX occurs with frequencies between 2.9 and 6.0 E-7 (<xref ref-type="table" rid="table1">Table 1</xref>).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Mutational frequencies of <italic>S. aureus.</italic></title><p>Newman for POM-HEX and several clinically utilized antibiotics. Experiments performed in technical duplicate and biological triplicate. Displayed are the means ± SD.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Antibiotic (MIC)</th><th>4× MIC</th><th>10× MIC</th></tr></thead><tbody><tr><td>Vancomycin (2 µg/mL)</td><td>&lt;1 E-10</td><td>&lt;1 E-10</td></tr><tr><td>Clindamycin (0.25 µg/mL)</td><td>&lt;1 E-10</td><td>&lt;1 E-10</td></tr><tr><td>Rifampicin (7.5 ng/mL)</td><td>8.96 ± 0.20 E-08</td><td>7.64 ± 2.10 E-08</td></tr><tr><td>Nafcillin (0.5 µg/mL)</td><td>&lt;1 E-10</td><td>&lt;1 E-10</td></tr><tr><td>Linezolid (1.67 µg/mL)</td><td>&lt;1 E-10</td><td>&lt;1 E-10</td></tr><tr><td>POM-HEX (3.13 µg/mL)</td><td>5.96 ± 1.60 E-07</td><td>2.92 ± 0.57 E-07</td></tr></tbody></table></table-wrap><p>The agreement between our forward and reverse genetic screens strongly suggests that two discrete predicted esterases, rather than a pool of redundant cellular esterases, activates the POM-HEX prodrug in <italic>S. aureus</italic>. Additionally, the finding that mutation in either <italic>frmB</italic> or <italic>gloB</italic> is sufficient to confer POM-HEX resistance suggests that the two enzymes may work in concert to bioconvert POM-HEX into HEX. As substantial sequence variation occurs among <italic>frmB</italic> and <italic>gloB</italic>, any prodrug therapeutics, which hijack these two enzymes, may not be broadly activated across all bacteria.</p></sec><sec id="s2-2"><title>FrmB and GloB are carboxylesterases with diverging substrate specificity</title><p>GloB is predicted to be a type II glyoxalase and a member of the large metallo-β-lactamase protein superfamily (INTERPRO IPR001279). Glyoxalase II enzymes, including the closely related GloB ortholog from <italic>S. scheiferi</italic>, catalyze the second step in the glyoxalase pathway that is responsible for the cellular conversion of methylglyoxal (a toxic glycolytic byproduct) to lactic acid (<xref ref-type="bibr" rid="bib40">Melino et al., 1998</xref>; <xref ref-type="bibr" rid="bib41">Mikati et al., 2020</xref>; <xref ref-type="bibr" rid="bib49">Stamp et al., 2010</xref>; <xref ref-type="bibr" rid="bib63">Zang et al., 2001</xref>). Conversely, FrmB orthologs hydrolyze p-nitrophenyl esters of short-chain fatty acids (C2–C6) and are thought to mediate detoxification of cellular formaldehyde (<xref ref-type="bibr" rid="bib15">Fellner et al., 2020</xref>; <xref ref-type="bibr" rid="bib19">Gonzalez et al., 2006</xref>).</p><p>We purified recombinant WT <italic>Sa</italic>FrmB and <italic>Sa</italic>GloB to evaluate the enzymatic function of each protein (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3A</xref>). We first assessed glyoxalase II activity using an assay, which couples hydrolysis of the glyoxalase II substrate, <italic>S</italic>-lactoylglutathione, to a change in absorbance (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3B</xref>). <italic>Sa</italic>GloB hydrolyzes <italic>S</italic>-lactoylglutathione with a specific activity comparable to previously characterized microbial type II glyoxalases, but <italic>Sa</italic>FrmB lacks appreciable glyoxalase activity.</p><p>We next assessed the ability of FrmB and GloB to hydrolyze p-nitrophenyl esters of short-chain fatty acids that have a photometric change upon hydrolysis (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3C</xref>). FrmB has modest activity against 4-nitrophenyl acetate and butyrate but no activity against 4-nitrophenyl trimethylacetate, suggesting a preference for unbranched fatty acids (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3C</xref>). This finding is in agreement with a previous characterization of FrmB as having a preference for short-chain and unbranched hydrophobic lipid substrates (<xref ref-type="bibr" rid="bib15">Fellner et al., 2020</xref>). Notably, GloB has no detectable activity against these substrates and neither GloB nor FrmB hydrolyzes 4-nitrophenyl trimethylacetate despite its structural similarity to POM-HEX. This may be due to the absence of the acyloxymethyl ether moiety in 4-nitrophenyl substrates, which is found in POM-prodrugs.</p><p>We also sought to directly assess the role of GloB and FrmB in POM-HEX activation. We incubated each enzyme with POM-HEX and characterized the products via <sup>31</sup>P-<sup>1</sup>H-heteronuclear single quantum coherence (HSQC) nuclear magnetic resonance (NMR). We have previously shown that GloB removes only one POM moiety, resulting in an accumulation of mono-POM-HEX (<xref ref-type="fig" rid="fig1">Figure 1B</xref>; <xref ref-type="bibr" rid="bib41">Mikati et al., 2020</xref>). Similarly, FrmB is capable of removing only one POM moiety (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4</xref>). We hypothesized that the two esterases may be stereoselective and incubated both enzymes with POM-HEX. We find that incubation of POM-HEX with GloB and FrmB still results in an accumulation of mono-POM-HEX, suggesting that neither of the two esterases efficiently cleaves the charged mono-POM species (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4</xref>).</p></sec><sec id="s2-3"><title>GloB and FrmB substrate specificity</title><p>To facilitate design of microbially targeted prodrug activation using these two enzymes, we next sought to extensively characterize GloB and FrmB substrate specificity. We employed a 32-compound ester substrate library, which fluoresces upon esterase activity (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>; <xref ref-type="bibr" rid="bib56">White et al., 2018</xref>). This library systematically varies ester substrate length, branching patterns, and ether and sulfide positioning, thereby allowing for the precise determination of structure-activity relationships. Kinetic measurements were performed for both FrmB and GloB over a range of substrate concentrations for the entire library, allowing for the calculation of catalytic efficiency (<italic>k</italic><sub>cat</sub>/<italic>K</italic><sub>m</sub>) for each enzyme and substrate (<xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref> and 2).</p><p>We find that FrmB and GloB tend to have the highest activity toward oxygen ethers (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplements 1</xref> and <xref ref-type="fig" rid="fig3s2">2</xref>). GloB has the highest activity against short-chain ethers (compounds 1–3), with some tolerance for branching at the first carbon beyond the ester carbonyl (compounds 7–9), while extensive branching strongly reduces activity (compound 10). Remarkably, GloB is tolerant of the extreme steric bulk introduced with the phenoxyacetic acid substrate, if the substrate contains an oxygen or sulfur ether (compound series 11). GloB exhibits a strong preference for oxygen at the β-position to the carbonyl over the γ-position but is indifferent to the positioning of sulfur. While GloB has a wider range of catalytic specificities, FrmB exhibits lower overall activity and a narrower range of catalytic efficiency. FrmB hydrolyzes unbranched substrates with little regard for chain length or the end-of-chain bulk within the tested substrates (compound series 1–3, 11). Branching at the position following the ester carbonyl (compound series 7–9, 12) is deleterious to FrmB activity. When oxygen is included in the chain, positioning at the β-position to the carbonyl is strongly preferred over the γ-position. For both GloB and FrmB, expanding the library of substrates tested will be revelatory of the true limitations of enzymatic activity.</p></sec><sec id="s2-4"><title>Importance of substrate specificity in vivo</title><p>While in vitro enzymatic substrate profiling is informative for how individual enzymes activate prodrugs, it may not reflect the complex biochemical processes happening in vivo, where additional cellular esterases may impact overall compound activation. We performed quantitative live cell imaging to measure the activation of pro-fluorescent substrates in real time. We loaded <italic>S. aureus</italic> onto a microfluidic device and imaged the cells by phase-contrast and epifluorescence microscopy before and while supplying pro-fluorescent compound. Intracellular fluorescence accumulates in response to the rapid introduction of substrate into the chamber and can be quantified through time.</p><p>We selected four pro-fluorescent substrates of varying catalytic efficiency against FrmB and GloB to test in our microfluidics experiments. In vitro, <italic>s</italic>ubstrate 1O displays high activity for both FrmB and GloB, 3C displays moderate activity for FrmB and GloB, 5O has moderate activity against GloB but poor activity against FrmB, and 9C has poor activity against both GloB and FrmB (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplements 1</xref> and <xref ref-type="fig" rid="fig3s2">2</xref>). Comparing the activation of these substrates through time, we find that our in vitro catalytic efficiency determination correlates well with our intracellular activation rates (<xref ref-type="fig" rid="fig3">Figure 3</xref>, <xref ref-type="video" rid="video1">Videos 1</xref>–<xref ref-type="video" rid="video4">4</xref>). Compound 1O, which exhibits high catalytic efficiency with both GloB and FrmB, reaches fluorescence saturation before the first 2 min time point. Compound 3C, which GloB and FrmB use with moderate activity, slowly activates over the duration of the experiment, and 5O and 9C, which have moderate-to-poor turnover with both GloB and FrmB, never appreciably activates during the 30 min of observation (<xref ref-type="fig" rid="fig3">Figure 3</xref>). As fluorescent activation is quantified per individual cell, we can also assess the uniformity of prodrug activation across the population. We observe remarkably homogenous activation of prodrugs across all observed cells (<xref ref-type="fig" rid="fig3">Figure 3</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>In vivo activation rates depend on ester promoiety selection.</title><p>Time series of activation of various fluorogenic substrates (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). Substrates were added into the microfluidics chamber at t = 10 minutes. On the right, quantification of individual cell or cell cluster fluorescence per area. Faint traces are individual cells and darker traces represent the mean of a given experiment. Each experiment was performed in biological duplicate, and each experiment is displayed in a different color (purple or green). Full movies viewable as <xref ref-type="video" rid="video1">Videos 1</xref>–<xref ref-type="video" rid="video4">4</xref>. Error bars denote SD.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>(1) Michaelis–Menten parameters for <italic>Sa</italic>FrmB.</title><p>Displayed are the results of three independent biological replicates in technical duplicate. (2) Michaelis–Menten parameters for <italic>Sa</italic>GloB. Displayed are the results of three independent biological replicates in technical duplicate.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-66657-fig3-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66657-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Profluorescent substrate library.</title><p>Activation of substrates via esterase action results in fluorescence.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66657-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Catalytic efficiency of GloB (<bold>A</bold>) and FrmB (<bold>B</bold>).</title><p>Numbers correspond to the structures displayed in Figure S5, compounds in the carbon series denoted in orange, oxygen series in blue, and sulfur series in green.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66657-fig3-figsupp2-v2.tif"/></fig></fig-group><media id="video1" mime-subtype="mp4" mimetype="video" xlink:href="elife-66657-video1.mp4"><label>Video 1.</label><caption><title>In vivo activation rates depend on ester promoiety selection.</title><p>Time series of fluorogenic ester substrate 1O activation. Substrate added at t = 10 min. Experiments were performed in biological duplicate.</p></caption></media><media id="video2" mime-subtype="mp4" mimetype="video" xlink:href="elife-66657-video2.mp4"><label>Video 2.</label><caption><title>In vivo activation rates depend on ester promoiety selection.</title><p>Time series of fluorogenic ester substrate 3C activation. Substrate added at t = 10 min. Experiments were performed in biological duplicate.</p></caption></media><media id="video3" mime-subtype="mp4" mimetype="video" xlink:href="elife-66657-video3.mp4"><label>Video 3.</label><caption><title>In vivo activation rates depend on ester promoiety selection.</title><p>Time series of fluorogenic ester substrate 5O activation. Substrate added at t = 10 min. Experiments were performed in biological duplicate.</p></caption></media><media id="video4" mime-subtype="mp4" mimetype="video" xlink:href="elife-66657-video4.mp4"><label>Video 4.</label><caption><title>In vivo activation rates depend on ester promoiety selection.</title><p>Time series of fluorogenic ester substrate 9C activation. Substrate added at t = 10 min. Experiments were performed in biological duplicate.</p></caption></media></sec><sec id="s2-5"><title>Three-dimensional structure of FrmB</title><p>To establish the structural basis for FrmB and GloB substrate specificity and enable future structure-guided prodrug therapeutic design, we solved the three-dimensional structures of both <italic>S. aureus</italic> FrmB and GloB. <italic>S. aureus</italic> FrmB was solved at 1.60 Å using molecular replacement with the low-temperature active alkaline esterase Est12 (PDB ID: 4RGY) as a search model (<xref ref-type="bibr" rid="bib25">Hu et al., 2015</xref>). Refinement parameters and statistics are summarized in <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>. A single dimer of FrmB is observable in the asymmetric unit, matching the apparent molecular weight of FrmB as observed via size-exclusion chromatography. The overall fold of FrmB is characteristic of the α/β-hydrolase fold. Six parallel β-strands and one anti-parallel β-strand pair form a central eight stranded β-sheet, which is surrounded by α-helices (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). One monomer of FrmB has electron density for a single magnesium ion, whereas the second monomer has two magnesium ions present.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Three-dimensional structure of FrmB.</title><p>(<bold>A</bold>) Overall fold, a-helices colored in orange and β-strands colored in purple. (<bold>B</bold>) Comparison between SaFrmB (orange) and its closest human ortholog, ESTD (gray). Active site residues denoted in orange spheres. (<bold>C</bold>, <bold>D</bold>) Docking of substrate 1O (sticks) in the active site of FrmB. surface view, red indicates highly hydrophobic and white hydrophilic residues. Surface view (<bold>C</bold>) or stick view with catalytic triad (<bold>D</bold>).</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Summary of crystallographic data collection and refinement statistics.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-66657-fig4-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66657-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Structural conservation of FrmB.</title><p>(<bold>A</bold>) Overall structural alignment of FrmB (orange) with <italic>S. pneumonia</italic> EstA (PDB:2UZ0), <italic>B. intestinalis</italic> ferulic acid esterase (PDB:5VOL), and deep sea bacteria Est12 (PDB4RGY). (<bold>B</bold>) Conservation of the serine hydrolase catalytic triad in FrmB and related proteins.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66657-fig4-figsupp1-v2.tif"/></fig></fig-group><p>A structural similarity search was performed using the DALI server to identify proteins related to <italic>Sa</italic>FrmB. The structure of <italic>Sa</italic>FrmB was most similar to the molecular replacement model, Est12 from deep sea bacteria (PDB ID 4RGY, root mean squared deviation [r.m.s.d.] = 1.020 Å), but also had similarity to <italic>Bacteroides intestinalis</italic> ferulic acid esterase <italic>Bi</italic>Fae1A (PDB ID 5VOL, r.m.s.d. = 1.137 Å) and <italic>Streptococcus pneumonia</italic> tributyrin esterase estA (PDB ID 2UZ0, r.m.s.d. = 1.329 Å) (<xref ref-type="bibr" rid="bib26">Kim et al., 2007</xref>; <xref ref-type="bibr" rid="bib46">Richardson et al., 2007</xref>; <xref ref-type="bibr" rid="bib55">Wefers et al., 2017</xref>). All structures display strong structural conservation including the positioning of the prototypic serine hydrolase catalytic triad: Ser120, Asp204, and His233 (<italic>S. aureus</italic>) (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). The most striking difference between the related structures is the flexible cap domain, implicated in substrate specificity of EstA and Est12 (<xref ref-type="bibr" rid="bib25">Hu et al., 2015</xref>; <xref ref-type="bibr" rid="bib26">Kim et al., 2007</xref>). While this manuscript was in preparation, an independent structure of FrmB was reported (<xref ref-type="bibr" rid="bib15">Fellner et al., 2020</xref>). The two structures are nearly identical (PDB ID 6ZHD, r.m.s.d = 0.433 Å), with slightly different positioning of the capping domain.</p><p>We compared <italic>Sa</italic>FrmB to its closest human ortholog, human esterase D (PDB ID 3fcx), finding moderate structural similarity both in the overall fold (r.m.s.d = 4.625 Å) and in the positioning of the catalytic triad (<xref ref-type="bibr" rid="bib60">Wu et al., 2009</xref>). However, <italic>Sa</italic>FrmB and human esterase D differ notably in the solvent-accessible surface around the active site, suggesting the potential for distinct substrate utilization, primarily driven by differential positioning of the cap domain (<xref ref-type="fig" rid="fig4">Figure 4B</xref>).</p><p>Using Autodock Vina, we modeled the highest catalytic efficiency substrate of FrmB, 1O, onto the active site of FrmB (<xref ref-type="bibr" rid="bib43">Morris et al., 2009</xref>; <xref ref-type="bibr" rid="bib50">Trott and Olson, 2010</xref>). Serine hydrolases classically bind the substrate carbonyl oxygen in an oxyanion hole, and substrate hydrolysis is initiated through attack of the catalytic serine on the ester carbonyl. The docking of 1O on FrmB mimics the initial state of a serine hydrolase reaction, with the carbonyl oxygen buried and the catalytic serine poised for attack (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). The pocket directly next to the oxyanion hole is relatively narrow, suggesting that steric hindrance explains the poor activity of FrmB against branched substrates. The active site pocket extends and opens significantly after passing by the oxyanion hole, supporting the capacity of FrmB to hydrolyze substrates that contain large steric groups distant from the carbonyl carbon, such as 11O.</p></sec><sec id="s2-6"><title>Three-dimensional structure of GloB</title><p>We also solved the structure of SaGloB to 1.65 Å, using selenomethionine (SeMet)-substituted GloB, and molecular replacement, using metallo-β-lactamase TTHA1623 from Thermus thermophilus as a search model (<xref ref-type="bibr" rid="bib61">Yamamura et al., 2009</xref>). Final structural refinement parameters and statistics are summarized in <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>. Four monomers of SaGloB are observed in the asymmetric unit with each displaying crystallographic symmetry. SaGloB exhibits the classic αβ/βα-fold that defines the metallo-β-lactamases, including glyoxalase II (<xref ref-type="fig" rid="fig5">Figure 5A</xref>; <xref ref-type="bibr" rid="bib5">Cameron et al., 1999</xref>; <xref ref-type="bibr" rid="bib22">Honek, 2015</xref>; <xref ref-type="bibr" rid="bib49">Stamp et al., 2010</xref>; <xref ref-type="bibr" rid="bib61">Yamamura et al., 2009</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Three-dimensional structure of GloB.</title><p>(<bold>A</bold>) Overall fold, a-alpha helices colored in green and β-strands colored in purple. (<bold>B</bold>) Comparison of SaGloB (green) and human GloB (gray). (<bold>C</bold>) Docking of the substrate 1O (sticks) in the active site of GloB. Left, partial cartoon view; right, surface view. White represents hydrophilic residues, whereas red represents hydrophobic residues. Zn ions indicated as silver spheres; water indicated as blue sphere.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Summary of crystallographic data collection and refinement statistics.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-66657-fig5-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66657-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Structural conservation of GloB.</title><p>(<bold>A</bold>) Overall structural alignment of GloB (green) with <italic>S. enterica</italic> YcbI (PDB:2XF4), <italic>T. thermophilus</italic> TTHA1623 (PDB:2ZWR), and <italic>A. thaliana</italic> glyoxalase II (PDB:1XM8). Zinc coordinating residues are colored in green spheres. (<bold>B</bold>) Positioning of the zinc coordinating residues (green spheres).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66657-fig5-figsupp1-v2.tif"/></fig></fig-group><p>As with <italic>Sa</italic>FrmB, a DALI server search was performed to identify proteins structurally similar to <italic>Sa</italic>GloB. <italic>Sa</italic>GloB displays extremely high similarity to the unusual type II glyoxalase YcbI from <italic>Salmonella enterica</italic> (PDB ID: 2XF4, r.m.s.d = 0.898 Å), to the molecular replacement search model TTHA1623 from <italic>Thermus thermophilus</italic> (PDB ID: 2ZWR, r.m.s.d. = 0.767), and to the <italic>Arabidopsis thaliana</italic> glyoxalase II (PDB ID: 1XM8, r.m.s.d = 1.165 Å), with the exception that <italic>At</italic>GloB has a 50 amino acid C-terminal extension (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>; <xref ref-type="bibr" rid="bib37">Marasinghe et al., 2005</xref>; <xref ref-type="bibr" rid="bib49">Stamp et al., 2010</xref>; <xref ref-type="bibr" rid="bib61">Yamamura et al., 2009</xref>). Also consistent with previously observed GloB structures, <italic>Sa</italic>GloB shows clear electron density for two zinc ions coordinated by six histidines and two aspartates (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>). Density for a water molecule is also visible and appears to be coordinated by the two zinc ions, as observed for human glyoxalase II (<xref ref-type="bibr" rid="bib5">Cameron et al., 1999</xref>).</p><p>Overlaying <italic>S. aureus</italic> GloB with <italic>Homo sapiens</italic> GloB (PDB: 1qh5) reveals that the two structures are remarkably similar (r.m.s.d = 1.249 Å), with a few notable exceptions. <italic>Hs</italic>GloB has two extensions: one, a 34-amino acid insertion; the other, a 32-amino acid C-terminal extension, both of which form α-helical features that abut the active site (<xref ref-type="fig" rid="fig5">Figure 5B</xref>; <xref ref-type="bibr" rid="bib5">Cameron et al., 1999</xref>). On the opposite side of the active site, <italic>Sa</italic>GloB has a 19-amino acid flexible loop, which is partially observed in the electron density. This loop is positioned such that it may cover the active site to sterically hinder substrate access (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Overall, these structural differences between <italic>Hs</italic>GloB and <italic>Sa</italic>GloB support the design of prodrug substrates selectively cleaved by <italic>S. aureus</italic>.</p><p>We modeled the highest catalytic efficiency substrate for GloB, 1O, onto our structure. Autodock places 1O with its carbonyl oxygen adjacent to the active site water (<xref ref-type="fig" rid="fig5">Figure 5C</xref>; <xref ref-type="bibr" rid="bib43">Morris et al., 2009</xref>; <xref ref-type="bibr" rid="bib50">Trott and Olson, 2010</xref>). The GloB active site channel appears moderately wide, explaining why extensively branched substrates are not tolerated. Toward the end of the active site channel, GloB appears to form a tunnel. This tunnel is not reached by substrate 1O, but presumably would be occupied in more sterically bulky substrates such as 11O. One arm of this tunnel is comprised of the highly flexible loop, which is only partially visible in our electron density, suggesting that during catalysis this flexible loop may accommodate larger substrates, such as 11O.</p></sec><sec id="s2-7"><title>Esterase specificity of human and mouse sera</title><p>We sought to evaluate whether ester promoieties could be designed for microbe-specific activation. Using the same 32-compound fluorescent substrate library, we determined each substrate’s serum half-life. Both reconstituted and fresh sera functions are comparable in their activity and substrate preferences (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>).</p><p>We performed full kinetic profiling of lyophilized human sera to define its ester substrate specificity. As sera is a mixture of multiple proteins instead of a single protein species, we report the <italic>V</italic><sub>max</sub>/<italic>K</italic><sub>m</sub> normalized to the total amount of protein added to the assay (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref>). As observed for FrmB and GloB (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2A–C</xref>), human sera has highest activity for oxygen and sulfur ether compounds. In contrast to FrmB and GloB, human sera is relatively uniform in its esterase activity across the substrate library. Short-chain substrates exhibit the highest catalytic efficiency, and though branching slightly reduces efficiency, it does not have as profound an impact as was observed with FrmB. The substrates displaying the poorest catalytic efficiency are universally the carbon series, in which added branching resulting in decreased substrate utilization.</p><p>As murine models are frequently used in the development and testing of novel pharmaceuticals, we also characterized the substrate preferences of mouse sera. Notably, mice are well known for their extremely active and broad serum esterase activity. Indeed, we find that mouse sera exhibit ~100-fold higher activity per mg serum protein than human sera (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplements 2D</xref> and <xref ref-type="fig" rid="fig6s3">3</xref>). This increase in activity is not uniform across the substrate library. Human sera is not as active on the carbon series and do comparatively better on the oxygen and sulfur ether compounds (<xref ref-type="fig" rid="fig6s3">Figure 6—figure supplement 3</xref>). Thus, our data suggest that mouse sera poorly predict human serum stability of ester prodrugs.</p><p>Finally, we sought to evaluate whether GloB and FrmB substrate specificities could be used for microbe-targeted prodrug design. As each esterase is likely to encounter multiple potential substrates in vivo, we utilized our modified <italic>V</italic><sub>max</sub>/<italic>K</italic><sub>m</sub> as a comparator. We performed pairwise analysis for each combination of FrmB and GloB against human and mouse sera (<xref ref-type="fig" rid="fig6">Figure 6A–D</xref>). Using a cutoff of 2<sup>10</sup>-fold enrichment in activity for the microbial enzymes over the serum enzymes, FrmB displays a preference over human sera for two compounds – 3C and 6C, whereas GloB displays a preference for six compounds – 2S, 3C, 10C, 11C, 11O, and 11S (<xref ref-type="fig" rid="fig6">Figure 6E</xref>). Conversely, mouse sera hydrolyze all compounds within this cutoff. Lowering the cutoff to a 2<sup>5</sup>-fold enrichment in catalytic efficiency over mouse sera, FrmB and GloB are both more specific for compound 2S, and GloB additionally displays specificity for compound 11O.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Comparison between microbial esterase and serum esterase catalytic efficiency.</title><p>(<bold>A–D</bold>) Volcano plots of catalytic efficiency. Displayed are the means of three independent experiments. p-values calculated as pairwise t-tests with Holm-Sidak correction for multiple comparisons. (<bold>A</bold>) Comparison between human sera and GloB, (<bold>B</bold>) human sera and FrmB, (<bold>C</bold>) mouse sera and GloB, and (<bold>D</bold>) mouse sera and FrmB. (<bold>E</bold>) Structures of ester substrates with 210 enrichment in catalytic efficiency for microbial esterases over human serum (left) or 25 enrichment over mouse serum. Dashed line indicates a p-value of 0.05.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>(1) Michaelis–Menten parameters for human sera.</title><p>Displayed are the results of three independent biological replicates in technical duplicate. (2) Michaelis–Menten parameters for mouse sera. Displayed are the results of three independent biological replicates in technical duplicate.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-66657-fig6-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66657-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Comparison of esterase activity between fresh and lyophilized human sera.</title><p>Points represent individual experiments; bars represent the mean ± SD of the four replicates.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66657-fig6-figsupp1-v2.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>Modified catalytic efficiency (pmol fluorescein produced * min<sup>−1</sup>*µg<sup>−1</sup> protein) of (<bold>A</bold>) human sera, (<bold>B</bold>) GloB, (<bold>C</bold>) FrmB, and (<bold>D</bold>) mouse sera.</title><p>X-axis corresponds to compound identities in Figure S5. Carbon containing compounds indicated in orange, oxygen in blue, and sulfur in green. Displayed are the means ± SD of three independent biological experiments.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66657-fig6-figsupp2-v2.tif"/></fig><fig id="fig6s3" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 3.</label><caption><title>Comparison of mouse and human sera.</title><p>(<bold>A</bold>) Modified catalytic efficiency (pmol fluorescein produced * min-1*µg-1 protein) of human and mouse sera. Displayed is a linear regression of the fit between mouse and human sera. (<bold>B</bold>) Volcano plot of catalytic efficiency. Displayed are the means of three independent experiments. p-values calculated as pairwise t-tests with Holm–Sidak correction for multiple comparisons. Dashed line indicates a p-value of 0.05.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66657-fig6-figsupp3-v2.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Targeted microbial delivery and activation of lipophilic ester prodrugs is a highly desirable strategy to enable the expansion of druggable targets within bacteria while simultaneously improving drug selectivity. Identification of microbe-specific promoieties is crucial to this goal. Here, we identify two discrete esterases in <italic>S. aureus</italic>, FrmB and GloB, that activate the carboxy ester prodrug, POM-HEX (<xref ref-type="fig" rid="fig7">Figure 7</xref>). Sequence homologues of FrmB and GloB are found broadly within microbes, though substantial sequence variation exists. FrmB and GloB have distinct ester substrate specificities, which are supported by the structures of their active sites. Importantly, enzymatic substrate specificity correlates with the rate of ester activation in live bacterial cells. Accordingly, simple modifications to ester prodrugs are sufficient to change their rates of activation in vivo.</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Model of antistaphylococcal prodrug activation.</title><p>Lipophilic carboxy ester prodrugs transit the cell membrane, are first activated by either GloB or FrmB and at least one additional enzyme, before inhibiting the cellular target.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66657-fig7-v2.tif"/></fig><p>Simple ester modifications can also change the pattern of prodrug activation. For the successful development of microbially targeted ester prodrugs, compounds must resist human enzymes. Here we demonstrate that, although commonly considered ‘nonspecific’, human serum esterases exhibit specific ester substrate preferences. These preferences are distinct from mouse sera, suggesting that rodents are an inadequate model for ester prodrug activation, serum stability, and thus therapeutic potential of ester produgs in humans. We also find that the staphylococcal esterases, FrmB and GloB, utilize distinct patterns of substrates compared to the preferred substrates utilized by human sera, indicating the feasibility of developing microbially targeted ester prodrugs.</p><p>Further evaluation of these ester promoieties and their potential metabolic and pharmacological liabilities is necessary before extensive clinical application. For example, while human serum de-esterifies carboxy-ester compounds, the liver also contributes significantly to drug metabolism (<xref ref-type="bibr" rid="bib29">Laizure et al., 2013</xref>; <xref ref-type="bibr" rid="bib32">Li et al., 2005</xref>). Hepatocytes not only express human carboxylesterases 1 and 2, but also include a suite of cytochrome P450 enzymes that are important in facilitating drug clearance. Introduction of lipophilic promoieties such as those tested in this work also increases the logP, or hydrophobicity, of the drug. For highly charged phosphonates, such as POM-HEX, this increase in lipophilicity may be beneficial in improving intestinal absorption or cell penetration, as has been observed for the beta lactam cefditoren, which was formulated with a POM-prodrug moiety as cefditoren-pivoxyl to improve bioavailability (<xref ref-type="bibr" rid="bib17">Fuchs, 2007</xref>). However, higher logP values raise concern for increased plasma protein binding and reduced efficacy in vivo. Whether increasing lipophilicity decreases the in vivo efficacy of these antibiotics remains to be tested, though decoration of the ester promoiety with more hydrophilic moieties is always possible.</p><p>Here, we have highlighted how <italic>S. aureus</italic> activates carboxy ester prodrugs. How microbes beyond <italic>S. aureus</italic> activate prodrugs, as well as the substrate specificities of pathogenic and commensal microbes, remains an important open question that will dictate the antimicrobial spectrum of a given ester prodrug. In past work, we have observed that lipophilic prodrugging with the POM-promoiety dramatically reduces compound activity in Gram-negative organisms (<xref ref-type="bibr" rid="bib10">Edwards et al., 2020</xref>). The cause for this reduction remains unclear but may be explained by a lack of activating esterases in the tested Gram-negatives or an exclusion of the prodrugged molecule from the cell. Understanding this variability in compound activation will ultimately determine how selective targeted prodrug anti-infectives can be as well as their potential applications. Overall, this work paves the way for structure-guided development of <italic>S. aureus</italic>-specific prodrugs and establishes a pipeline for the identification of additional microbial prodrug-activating enzymes. We anticipate that these approaches will both guide the development of novel antimicrobials and lead to a more robust arsenal of anti-infective compounds with targeted specificity for the microbe over the human host.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th>Reagent type <break/>(species) or resource</th><th>Designation</th><th>Source or reference</th><th>Identifiers</th><th>Additional information</th></tr></thead><tbody><tr><td>Gene (<italic>Staphylococcus aureus</italic>)</td><td>GloB</td><td>GenBank</td><td>WP_001223008.1</td><td>GloII</td></tr><tr><td>Gene (<italic>Staphylococcus aureus</italic>)</td><td>FrmB</td><td>GenBank</td><td/><td>estA</td></tr><tr><td>Strain, strain background (<italic>Staphylococcus aureus</italic>)</td><td>JE2</td><td>BEI Resources</td><td>NR-46543</td><td/></tr><tr><td>Strain, strain background (<italic>Staphylococcus aureus</italic>)</td><td>NE64</td><td>Nebraska Transposon Mutant Library</td><td>Hypothetical protein</td><td>Available from BEI Resources as: NR-48501</td></tr><tr><td>Strain, strain background (<italic>Staphylococcus aureus</italic>)</td><td>NE145</td><td>Nebraska Transposon Mutant Library</td><td>protoporphyrinogen oxidase</td><td>Available from BEI Resources as: NR-48501</td></tr><tr><td>Strain, strain background (<italic>Staphylococcus aureus</italic>)</td><td>NE202</td><td>Nebraska Transposon Mutant Library</td><td>ABC transporter, ATP-binding protein, MsbA family</td><td>Available from BEI Resources as: NR-48501</td></tr><tr><td>Strain, strain background (<italic>Staphylococcus aureus</italic>)</td><td>NE223</td><td>Nebraska Transposon Mutant Library</td><td>hydroxyacylglutathione hydrolase</td><td>Available from BEI Resources as: NR-48501</td></tr><tr><td>Strain, strain background (<italic>Staphylococcus aureus</italic>)</td><td>NE293</td><td>Nebraska Transposon Mutant Library</td><td>staphylococcal accessory regulator Rot</td><td>Available from BEI Resources as: NR-48501</td></tr><tr><td>Strain, strain background (<italic>Staphylococcus aureus</italic>)</td><td>NE355</td><td>Nebraska Transposon Mutant Library</td><td>tributyrin esterase</td><td>Available from BEI Resources as: NR-48501</td></tr><tr><td>Strain, strain background (<italic>Staphylococcus aureus</italic>)</td><td>NE364</td><td>Nebraska Transposon Mutant Library</td><td>NAD-dependent epimerase/dehydratase family protein</td><td>Available from BEI Resources as: NR-48501</td></tr><tr><td>Strain, strain background (<italic>Staphylococcus aureus</italic>)</td><td>NE377</td><td>Nebraska Transposon Mutant Library</td><td>pyrroline-5-carboxylate reductase</td><td>Available from BEI Resources as: NR-48501</td></tr><tr><td>Strain, strain background (<italic>Staphylococcus aureus</italic>)</td><td>NE386</td><td>Nebraska Transposon Mutant Library</td><td>Hypothetical protein</td><td>Available from BEI Resources as: NR-48501</td></tr><tr><td>Strain, strain background (<italic>Staphylococcus aureus</italic>)</td><td>NE478</td><td>Nebraska Transposon Mutant Library</td><td>peptide ABC transporter, permease protein</td><td>Available from BEI Resources as: NR-48501</td></tr><tr><td>Strain, strain background (<italic>Staphylococcus aureus</italic>)</td><td>NE503</td><td>Nebraska Transposon Mutant Library</td><td>conserved hypothetical protein</td><td>Available from BEI Resources as: NR-48501</td></tr><tr><td>Strain, strain background (<italic>Staphylococcus aureus</italic>)</td><td>NE520</td><td>Nebraska Transposon Mutant Library</td><td>sensor histidine kinase SaeS</td><td>Available from BEI Resources as: NR-48501</td></tr><tr><td>Strain, strain background (<italic>Staphylococcus aureus</italic>)</td><td>NE532</td><td>Nebraska Transposon Mutant Library</td><td>PTS system, mannitol specific IIBC component</td><td>Available from BEI Resources as: NR-48501</td></tr><tr><td>Strain, strain background (<italic>Staphylococcus aureus</italic>)</td><td>NE541</td><td>Nebraska Transposon Mutant Library</td><td>alkaline phosphatase synthesis transcriptional regulatory protein</td><td>Available from BEI Resources as: NR-48501</td></tr><tr><td>Strain, strain background (<italic>Staphylococcus aureus</italic>)</td><td>NE621</td><td>Nebraska Transposon Mutant Library</td><td>Hypothetical protein</td><td>Available from BEI Resources as: NR-48501</td></tr><tr><td>Strain, strain background (<italic>Staphylococcus aureus</italic>)</td><td>NE812</td><td>Nebraska Transposon Mutant Library</td><td>tetrahydrodipicolinate acetyltransferase</td><td>Available from BEI Resources as: NR-48501</td></tr><tr><td>Strain, strain background (<italic>Staphylococcus aureus</italic>)</td><td>NE874</td><td>Nebraska Transposon Mutant Library</td><td>Hypothetical protein</td><td>Available from BEI Resources as: NR-48501</td></tr><tr><td>Strain, strain background (<italic>Staphylococcus aureus</italic>)</td><td>NE929</td><td>Nebraska Transposon Mutant Library</td><td>acetyl-CoA carboxylase, biotin carboxylase</td><td>Available from BEI Resources as: NR-48501</td></tr><tr><td>Strain, strain background (<italic>Staphylococcus aureus</italic>)</td><td>NE937</td><td>Nebraska Transposon Mutant Library</td><td>tandem lipoprotein</td><td>Available from BEI Resources as: NR-48501</td></tr><tr><td>Strain, strain background (<italic>Staphylococcus aureus</italic>)</td><td>NE949</td><td>Nebraska Transposon Mutant Library</td><td>Putative Transposase</td><td>Available from BEI Resources as: NR-48501</td></tr><tr><td>Strain, strain background (<italic>Staphylococcus aureus</italic>)</td><td>NE1039</td><td>Nebraska Transposon Mutant Library</td><td>excinuclease ABC, A subunit</td><td>Available from BEI Resources as: NR-48501</td></tr><tr><td>Strain, strain background (<italic>Staphylococcus aureus</italic>)</td><td>NE1051</td><td>Nebraska Transposon Mutant Library</td><td>Hypothetical protein</td><td>Available from BEI Resources as: NR-48501</td></tr><tr><td>Strain, strain background (<italic>Staphylococcus aureus</italic>)</td><td>NE1071</td><td>Nebraska Transposon Mutant Library</td><td>Hypothetical protein</td><td>Available from BEI Resources as: NR-48501</td></tr><tr><td>Strain, strain background (<italic>Staphylococcus aureus</italic>)</td><td>NE1118</td><td>Nebraska Transposon Mutant Library</td><td>dihydrolipoamide dehydrogenase</td><td>Available from BEI Resources as: NR-48501</td></tr><tr><td>Strain, strain background (<italic>Staphylococcus aureus</italic>)</td><td>NE1127</td><td>Nebraska Transposon Mutant Library</td><td>gamma-hemolysin component B</td><td>Available from BEI Resources as: NR-48501</td></tr><tr><td>Strain, strain background (<italic>Staphylococcus aureus</italic>)</td><td>NE1173</td><td>Nebraska Transposon Mutant Library</td><td>tRNA pseudouridine synthase A</td><td>Available from BEI Resources as: NR-48501</td></tr><tr><td>Strain, strain background (<italic>Staphylococcus aureus</italic>)</td><td>NE1225</td><td>Nebraska Transposon Mutant Library</td><td>ABC transporter, ATP-binding protein</td><td>Available from BEI Resources as: NR-48501</td></tr><tr><td>Strain, strain background (<italic>Staphylococcus aureus</italic>)</td><td>NE1238</td><td>Nebraska Transposon Mutant Library</td><td>transcriptional regulator, TetR family</td><td>Available from BEI Resources as: NR-48501</td></tr><tr><td>Strain, strain background (<italic>Staphylococcus aureus</italic>)</td><td>NE1283</td><td>Nebraska Transposon Mutant Library</td><td>Hypothetical protein</td><td>Available from BEI Resources as: NR-48501</td></tr><tr><td>Strain, strain background (<italic>Staphylococcus aureus</italic>)</td><td>NE1296</td><td>Nebraska Transposon Mutant Library</td><td>hydroxyacylglutathione hydrolase</td><td>Available from BEI Resources as: NR-48501</td></tr><tr><td>Strain, strain background (<italic>Staphylococcus aureus</italic>)</td><td>NE1486</td><td>Nebraska Transposon Mutant Library</td><td>phosphonate ABC transporter, permease protein</td><td>Available from BEI Resources as: NR-48501</td></tr><tr><td>Strain, strain background (<italic>Staphylococcus aureus</italic>)</td><td>NE1505</td><td>Nebraska Transposon Mutant Library</td><td>tributyrin esterase</td><td>Available from BEI Resources as: NR-48501</td></tr><tr><td>Strain, strain background (<italic>Staphylococcus aureus</italic>)</td><td>NE1519</td><td>Nebraska Transposon Mutant Library</td><td>Hypothetical Alkaline Phosphatase</td><td>Available from BEI Resources as: NR-48501</td></tr><tr><td>Strain, strain background (<italic>Staphylococcus aureus</italic>)</td><td>NE1547</td><td>Nebraska Transposon Mutant Library</td><td>Hypothetical protein</td><td>Available from BEI Resources as: NR-48501</td></tr><tr><td>Strain, strain background (<italic>Staphylococcus aureus</italic>)</td><td>NE1610</td><td>Nebraska Transposon Mutant Library</td><td>Hypothetical protein</td><td>Available from BEI Resources as: NR-48501</td></tr><tr><td>Strain, strain background (<italic>Staphylococcus aureus</italic>)</td><td>NE1682</td><td>Nebraska Transposon Mutant Library</td><td>PfkB family kinase</td><td>Available from BEI Resources as: NR-48501</td></tr><tr><td>Strain, strain background (<italic>Staphylococcus aureus</italic>)</td><td>NE1723</td><td>Nebraska Transposon Mutant Library</td><td>type I restriction-modification system, M subunit</td><td>Available from BEI Resources as: NR-48501</td></tr><tr><td>Strain, strain background (<italic>Escherichia coli</italic>)</td><td>BL21 (DE3)</td><td>Sigma</td><td>CMC0014</td><td>Chemically Competent</td></tr><tr><td>Biological sample (<italic>Homo sapiens</italic>)</td><td>Fresh Human Serum</td><td>This paper</td><td/><td>Whole blood was collected from a willing volunteer into untreated BD vacutainer tubes (BD, BD366430), allowed to clot, and aggregates were removed via centrifugation</td></tr><tr><td>Biological sample (<italic>Homo sapiens</italic>)</td><td>Lyophilized Human Serum</td><td>Rockland Inc</td><td>D314-5</td><td/></tr><tr><td>Biological sample (<italic>Mus musculus</italic>)</td><td>Lyophilized Mouse Serum</td><td>Rockland Inc</td><td>D308-5</td><td/></tr><tr><td>Recombinant DNA reagent</td><td>pET28a-<italic>Sa</italic>FrmB</td><td>This paper</td><td/><td><italic>E. coli</italic> expression plasmid for <italic>Sa</italic>FrmB with cleavable HIS tag.</td></tr><tr><td>Recombinant DNA reagent</td><td>pET28a-<italic>Sa</italic>GloB</td><td>This paper</td><td/><td><italic>E. coli</italic> expression plasmid for <italic>Sa</italic>GloB with cleavable HIS tag.</td></tr><tr><td>Recombinant DNA reagent</td><td>BG1861-<italic>Sa</italic>GloB</td><td>This paper</td><td/><td><italic>E. coli</italic> expression plasmid for <italic>Sa</italic>GloB with HIS tag.</td></tr><tr><td>Recombinant DNA reagent</td><td>BG1861-<italic>Sa</italic>FrmB</td><td>This paper</td><td/><td><italic>E. coli</italic> expression plasmid for <italic>Sa</italic>FrmB with HIS tag.</td></tr><tr><td>Sequence-based reagent</td><td>NWMN_0144_F</td><td>This paper</td><td>PCR Primer</td><td>TTTTCCTGATCCTGATTCAC</td></tr><tr><td>Sequence-based reagent</td><td>NWMN_0144_R</td><td>This paper</td><td>PCR Primer</td><td>ATGATGCTTCCATGTTTGTT</td></tr><tr><td>Sequence-based reagent</td><td>NWMN_0306_F</td><td>This paper</td><td>PCR Primer</td><td>AATACACCGGGTAACACAAC</td></tr><tr><td>Sequence-based reagent</td><td>NWMN_0306_R</td><td>This Paper</td><td>PCR Primer</td><td>CGTTTTGTTGAGCTAATTCC</td></tr><tr><td>Sequence-based reagent</td><td>NWMN_0309_F</td><td>This paper</td><td>PCR Primer</td><td>ACCATGCTTAAAGGGATTTT</td></tr><tr><td>Sequence-based reagent</td><td>NWMN_0309_R</td><td>This Paper</td><td>PCR Primer</td><td>TGTCACCTAAGTCAACACCA</td></tr><tr><td>Sequence-based reagent</td><td>NWMN_0407 (lpl4nm) _F</td><td>This paper</td><td>PCR Primer</td><td>CCGTTGGAGATAGGAAGTTA</td></tr><tr><td>Sequence-based reagent</td><td>NWMN_0407 (lpl4nm) _R</td><td>This paper</td><td>PCR Primer</td><td>TTTGTGCTTCTTTTGAACCT</td></tr><tr><td>Sequence-based reagent</td><td>NWMN_0654_F</td><td>This paper</td><td>PCR Primer</td><td>GAAAATGGAAGACTGATTGC</td></tr><tr><td>Sequence-based reagent</td><td>NWMN_0654_R</td><td>This paper</td><td>PCR Primer</td><td>TAATGCATCTGACAAAGTCG</td></tr><tr><td>Sequence-based reagent</td><td>NWMN_0762_F</td><td>This paper</td><td>PCR Primer</td><td>GGTGAAGTTTTGGACGATAA</td></tr><tr><td>Sequence-based reagent</td><td>NWMN_0762_R</td><td>This paper</td><td>PCR Primer</td><td>TTTTCATCTGTCCGACTTTT</td></tr><tr><td>Sequence-based reagent</td><td>NWMN_1101_F</td><td>This paper</td><td>PCR Primer</td><td>TCCACCTATTGGAATTATCG</td></tr><tr><td>Sequence-based reagent</td><td>NWMN_1101_R</td><td>This paper</td><td>PCR Primer</td><td>AGACGTTCAATTTCAGTGCT</td></tr><tr><td>Sequence-based reagent</td><td>NWMN_1192 (pgsA) _F</td><td>This paper</td><td>PCR Primer</td><td>TGGGACGAAGTAATTACAGTT</td></tr><tr><td>Sequence-based reagent</td><td>NWMN_1192 (pgsA) _R</td><td>This paper</td><td>PCR Primer</td><td>ATATCCCCCTTGTATCGTTT</td></tr><tr><td>Sequence-based reagent</td><td>NWMN_1308 (dapD) _F</td><td>This paper</td><td>PCR Primer</td><td>TCTATTCGTGGAGGTACGAT</td></tr><tr><td>Sequence-based reagent</td><td>NWMN_1308 (dapD) _R</td><td>This paper</td><td>PCR Primer</td><td>ATCGTATGTGAGCCATTACC</td></tr><tr><td>Sequence-based reagent</td><td>NWMN_1410_F</td><td>This paper</td><td>PCR Primer</td><td>CGATAAACCTAAACCACTCG</td></tr><tr><td>Sequence-based reagent</td><td>NWMN_1410_R</td><td>This paper</td><td>PCR Primer</td><td>ATAAACAATGCTTGCCAAAT</td></tr><tr><td>Sequence-based reagent</td><td>NWMN_1505_F</td><td>This paper</td><td>PCR Primer</td><td>TGAAGGTGAATTAAGCGATG</td></tr><tr><td>Sequence-based reagent</td><td>NWMN_1505_R</td><td>This paper</td><td>PCR Primer</td><td>TGCTATTCCCAATTTGTTCA</td></tr><tr><td>Sequence-based reagent</td><td>NWMN_1655_F</td><td>This paper</td><td>PCR Primer</td><td>GAATTGTTGCAATTTAATGGT</td></tr><tr><td>Sequence-based reagent</td><td>NWMN_1655_R</td><td>This paper</td><td>PCR Primer</td><td>AACGTAATCATGCTCCATTC</td></tr><tr><td>Sequence-based reagent</td><td>NWMN_1679_F</td><td>This paper</td><td>PCR Primer</td><td>CCATGGGAAAAATTAGACAA</td></tr><tr><td>Sequence-based reagent</td><td>NWMN_1679_R</td><td>This paper</td><td>PCR Primer</td><td>AAATATCGCCTCACCTTTTT</td></tr><tr><td>Sequence-based reagent</td><td>NWMN_1723 (hemY) _F</td><td>This paper</td><td>PCR Primer</td><td>GCCGAATACACATCCATTAT</td></tr><tr><td>Sequence-based reagent</td><td>NWMN_1723 (hemY) _R</td><td>This paper</td><td>PCR Primer</td><td>AACCTTTGTCTCTGCTTCAA</td></tr><tr><td>Sequence-based reagent</td><td>NWMN_1851 (nadC) _F</td><td>This paper</td><td>PCR Primer</td><td>AGCCATTTTAGCACCATAAA</td></tr><tr><td>Sequence-based reagent</td><td>NWMN_1851 (nadC)_R</td><td>This paper</td><td>PCR Primer</td><td>TAGAATCCTGTCCTCCTGAA</td></tr><tr><td>Sequence-based reagent</td><td>NWMN_2057 (mtlF)_F</td><td>This paper</td><td>PCR Primer</td><td>TGTACAACGGTGTTGTTTTG</td></tr><tr><td>Sequence-based reagent</td><td>NWMN_2057 (mtlF)_R</td><td>This paper</td><td>PCR Primer</td><td>CGGTGAATAGTACGAGAGGA</td></tr><tr><td>Sequence-based reagent</td><td>NWMN_2528_F</td><td>This paper</td><td>PCR Primer</td><td>ACTGATGCTTTACCAGAAAC</td></tr><tr><td>Sequence-based reagent</td><td>NWMN_2528_R</td><td>This paper</td><td>PCR Primer</td><td>TCAGCGGTAGTAATAAAGGT</td></tr><tr><td>Chemical compound, drug</td><td>POM-HEX</td><td><xref ref-type="bibr" rid="bib56">White et al., 2018</xref></td><td/><td/></tr><tr><td>Chemical compound, drug</td><td>Hemi-HEX</td><td><xref ref-type="bibr" rid="bib34">Lin et al., 2020</xref></td><td/><td/></tr><tr><td>Chemical compound, drug</td><td>HEX</td><td>Lin et al. 2018</td><td/><td/></tr><tr><td>Chemical compound, drug</td><td>Fluorescent Prosubstrates</td><td><xref ref-type="bibr" rid="bib56">White et al., 2018</xref></td><td/><td/></tr><tr><td>Chemical compound, drug</td><td>S-D-lactoylglutathione</td><td>Sigma-Aldrich</td><td>L7140</td><td/></tr><tr><td>Chemical compound, drug</td><td>4-Nitrophenyl acetate</td><td>Sigma-Aldrich</td><td>N8130</td><td/></tr><tr><td>Chemical compound, drug</td><td>4-Nitrophenyl butyrate</td><td>Sigma-Aldrich</td><td>N9876</td><td/></tr><tr><td>Chemical compound, drug</td><td>4-Nitrophenyl trimethyl acetate</td><td>Sigma-Aldrich</td><td>135046</td><td/></tr><tr><td>Software, algorithm</td><td>WhatsGNU</td><td><xref ref-type="bibr" rid="bib44">Moustafa and Planet, 2020</xref></td><td/><td><ext-link ext-link-type="uri" xlink:href="https://github.com/ahmedmagds/WhatsGNU">https://github.com/ahmedmagds/WhatsGNU</ext-link></td></tr><tr><td>Software, algorithm</td><td>MUSCLE</td><td><xref ref-type="bibr" rid="bib31">Letunic and Bork, 2019</xref></td><td/><td><ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/Tools/msa/muscle/">https://www.ebi.ac.uk/Tools/msa/muscle/</ext-link></td></tr><tr><td>Software, algorithm</td><td>iTOL</td><td><xref ref-type="bibr" rid="bib36">Madeira et al., 2019</xref></td><td/><td><ext-link ext-link-type="uri" xlink:href="https://itol.embl.de/">https://itol.embl.de/</ext-link></td></tr><tr><td>Software, algorithm</td><td>HKL-3000</td><td><xref ref-type="bibr" rid="bib42">Minor et al., 2006</xref></td><td/><td><ext-link ext-link-type="uri" xlink:href="https://hkl-xray.com/hkl-3000">https://hkl-xray.com/hkl-3000</ext-link></td></tr><tr><td>Software, algorithm</td><td>PHASER</td><td><xref ref-type="bibr" rid="bib38">McCoy et al., 2007</xref></td><td/><td/></tr><tr><td>Software, algorithm</td><td>COOT</td><td><xref ref-type="bibr" rid="bib11">Emsley and Cowtan, 2004</xref></td><td/><td><ext-link ext-link-type="uri" xlink:href="https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/">https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/</ext-link></td></tr><tr><td>Software, algorithm</td><td>PHENIX</td><td><xref ref-type="bibr" rid="bib1">Adams et al., 2010</xref></td><td/><td><ext-link ext-link-type="uri" xlink:href="http://www.phenix-online.org/">http://www.phenix-online.org/</ext-link></td></tr><tr><td>Software, algorithm</td><td>ChemDraw3D</td><td><ext-link ext-link-type="uri" xlink:href="https://www.cambridgesoft.com/Ensemble_for_Chemistry/details/Default.aspx?fid=13&amp;pid=668">https://www.cambridgesoft.com/Ensemble_for_Chemistry/details/Default.aspx?fid=13&amp;pid=668</ext-link></td><td/><td/></tr><tr><td>Software, algorithm</td><td>AutoDock Tools 1.5.7</td><td><xref ref-type="bibr" rid="bib43">Morris et al., 2009</xref></td><td/><td><ext-link ext-link-type="uri" xlink:href="http://autodock.scripps.edu/resources/adt">http://autodock.scripps.edu/resources/adt</ext-link></td></tr><tr><td>Software, algorithm</td><td>AutoDock Vina</td><td><xref ref-type="bibr" rid="bib50">Trott and Olson, 2010</xref></td><td/><td><ext-link ext-link-type="uri" xlink:href="http://vina.scripps.edu/">http://vina.scripps.edu/</ext-link></td></tr><tr><td>Software, algorithm</td><td>GraphPad Prism</td><td><ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com/scientific-software/prism/">https://www.graphpad.com/scientific-software/prism/</ext-link></td><td/><td/></tr><tr><td>Other</td><td>CellASIC ONIX2 microfluidic plate</td><td>EMD-Millipore</td><td>B04A-03-5PK</td><td/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Materials</title><p>POM-HEX, Hemi-HEX, and HEX were synthesized and resuspended in 100% DMSO as described previously (<xref ref-type="bibr" rid="bib34">Lin et al., 2020</xref>). Fluorescent ester compounds were generously provided by the laboratory of Geoffrey Hoops (Butler University), and synthesis and characterization have been previously described (<xref ref-type="bibr" rid="bib56">White et al., 2018</xref>). Pooled, delipidated, defibrinated, and lyophilized human and mouse serum was obtained from Rockland Inc.</p></sec><sec id="s4-2"><title>Quantification of resistance</title><p>Half-maximal inhibitory concentration (IC<sub>50</sub>) determination was performed using microtiter broth dilution in clear 96-well plates (<xref ref-type="bibr" rid="bib14">European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the ES of CM and ID (ESCMID), 2000</xref>). Briefly, POM-HEX was added to 75 µL LB media at a final concentration of 20–50 µM POM-HEX and 0.5% DMSO, with POM-HEX concentrations varying according to resistant strain. Subsequently, POM-HEX was serially diluted in LB media containing 0.5% DMSO for a total of 10 dilutions. Two wells were left without drug, one used to define 100% growth, and the other used to control for media contamination and to define 0% growth. Seventy-five microliters of mid-log phase <italic>S. aureus</italic> diluted to 1 × 10<sup>5</sup> colony forming units/mL were subsequently added to the plate. Following inoculation, plates were incubated at 37°C with shaking, and OD<sub>600</sub> measurements were taken every 20 min for a total of 16 hr. Half-maximal inhibitory concentrations (IC<sub>50</sub>) were determined by fitting the OD<sub>600</sub> of each condition following 10 hr of growth to a nonlinear regression using GraphPad Prism software. Experiments were performed in triplicate with technical duplicates.</p><p>Generation of POM-HEX resistant strains was performed by plating log-phase <italic>S. aureus</italic> Newman on LB agar containing 3.33 μM POM-HEX and incubating at 37°C overnight. Surviving single colonies were grown overnight in LB media and frozen in 10% glycerol for long term storage. All assays were performed from fresh overnight inoculations from glycerol stocks.</p></sec><sec id="s4-3"><title>Antibiotic resistance frequency</title><p>Antibiotic resistance frequency was determined on LB agar plates containing 4× and 10×, the minimum inhibitory concentrations of several antibiotics. MICs were determined for <italic>S. aureus</italic> Newman in liquid LB media. Antibiotics (MIC for <italic>S. aureus</italic> Newman) tested were as follows: Vancomycin (2 µg/mL), Clindamycin (0.25 µg/mL), Rifampicin (7.5 ng/mL), Nafcillin (0.5 µg/mL), Linezolid (1.67 µg/mL), and POM-HEX (3.13 µg/mL). Briefly, <italic>S. aureus</italic> Newman was grown in LB media to late log-phase and centrifuged at 4000 × g for 15 min before resuspension at an OD<sub>600 nm</sub> of 30 (~1E11 CFU/mL) in LB media. One hundred microliter aliquots of concentrated <italic>S. aureus</italic> was plated in duplicate on selective and non-selective plates and incubated at 37°C. After 24 hr, mutation rates were calculated by counting the number of colonies present and dividing by the total number of colonies plated. Experiments were performed in triplicate.</p></sec><sec id="s4-4"><title>Whole-genome sequencing and variant discovery</title><p>Genomic DNA integrity was determined using Agilent 4200 Tapestation. Library preparation was performed with 0.25–0.5 µg of DNA. DNA was fragmented using a Covaris E220 sonicator using peak incident power 175, duty factor 10%, cycles per burst 200 for 240 s at 4°C. DNA was blunt ended, had an A base added to the 3’ ends, and then had Illumina sequencing adapters ligated to the ends. Ligated fragments were then amplified for nine cycles using primers incorporating unique dual index tags. Fragments were sequenced on an Illumina MiSeq using paired-end reads extending 150 bases.</p><p>For the analysis, the WT-assembled genomic sequence for <italic>S. aureus</italic> Newman was retrieved from GenBank (accession number AP009351.1), and the paired-end reads were aligned to this genome using Novoalign v3.03 (Novocraft Technologies). Duplicates were removed and variants were called using SAMtools (<xref ref-type="bibr" rid="bib33">Li et al., 2009</xref>). SNPs were filtered against the sequenced parental strain, and genetic variants were annotated using SnpEff v4.3 (<xref ref-type="bibr" rid="bib7">Cingolani et al., 2012</xref>). Whole-genome sequencing data is available in the NCBI BioProject database and Sequence Read Archive under the BioProject ID PRJNA648156. All identified variants were verified via Sanger sequencing using the gene-specific primers found in the key resources table. Amplicons were sequenced by GeneWiz Inc (Bejing, China).</p></sec><sec id="s4-5"><title>WhatsGNU analysis</title><p>The <italic>S. aureus</italic> database was used to produce WhatsGNU proteomic reports for all the strains using WhatsGNU_main.py script in the ortholog mode. Eighteen <italic>S. aureus</italic> (nine atopic dermatitis [AD] and nine soft and skin tissue infection [SSTI]) isolates from an ongoing project representing different clonal complexes (CC1/5/8/22/30) were used for the comparison. The CC details for the 18 isolates are provided in <xref ref-type="supplementary-material" rid="fig2sdata4">Figure 2—source data 4</xref>. The reports were then used to produce a heat map of the GNU scores of GloB and FrmB using the heat map function in the WhatsGNU_plotter.py script. The heatmap was annotated with the ortholog variant rarity index where ‘r’ represents a rare GNU score (in the context of other alleles in the same protein ortholog group).</p></sec><sec id="s4-6"><title>Phylogenetic tree construction</title><p>Sequences of GloB, FrmB, and RpoB orthologs were retrieved from NCBI using the BlastP function with each organism on the tree as an individual search set. Of the returned sequences, the first complete sequence with the lowest E-value was selected for further analysis. Organisms were selected to include a wide variety of pathogenic and commensal microbes (<xref ref-type="bibr" rid="bib62">Yatsunenko et al., 2012</xref>). In one instance, several of the top <italic>E. coli</italic> sequences were found to be highly similar to <italic>S. aureus</italic>, and on further analysis, we discovered that the original sequencing samples had high levels of <italic>S. aureus</italic> reads. These contaminated sequences were disregarded in our analysis. Sequence alignment was performed using MUSCLE using the default parameters, and the unrooted phylogenetic trees were visualized using iTOL (<xref ref-type="bibr" rid="bib31">Letunic and Bork, 2019</xref>; <xref ref-type="bibr" rid="bib36">Madeira et al., 2019</xref>).</p></sec><sec id="s4-7"><title>Recombinant expression and purification of FrmB and GloB</title><p>WT <italic>frmB</italic> and <italic>gloB</italic> sequences from <italic>S. aureus</italic> Newman were cloned into the BG1861 vector by GeneWiz Inc to introduce a hexahistidine tag (<xref ref-type="bibr" rid="bib2">Alexandrov et al., 2004</xref>). The resultant plasmids were transformed into Stellar chemically competent cells (Clontech Laboratories), selected with carbenicillin, and the sequence was confirmed by Sanger sequencing. Subsequently, plasmids were transformed into chemically competent BL21 (DE3) cells and selected with 50 µg/mL ampicillin. Overnight liquid cultures were diluted 1:500 into LB media supplemented with ampicillin, grown shaking at 220 rpm to an OD<sub>600</sub> of 0.5–0.8 at 37°C, chilled to 16°C, and induced with 0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) for 16–20 hr. Cells were harvested by centrifugation at 6000 × g for 10 min at 4°C. The cell pellet was lysed by sonication in 50 mL lysis buffer containing 25 mM Tris–HCl (pH 7.5), 250 mM NaCl, 20 mM imidazole, 1 mM MgCl<sub>2</sub>, 10% glycerol, and 200 µM phenylmethylsulfonyl fluoride (PMSF). Cell debris were removed by centrifugation twice at 20,000 × g for 20 min. The hexahistidine-tagged proteins were affinity purified from soluble lysate using nickel agarose beads (Gold Biotechnology). Bound protein was washed with 50 mL lysis buffer before elution using 5 mL of elution buffer containing 25 mM Tris–HCl pH 7.5, 250 mM NaCl, 300 mM imidazole, 1 mM MgCl<sub>2</sub>, 10% glycerol. Affinity purified protein was further purified over a HiLoad 16/60 Superdex 200 gel filtration column (GE Healthsciences) using an AKTA Explorer. FPLC buffer contained 25 mM Tris–HCl pH 7.5, 250 mM NaCl, 1 mM MgCl<sub>2</sub>, and 10% glycerol. Fractions containing &gt;90% pure protein (evaluated by SDS–PAGE) were concentrated using an Amicon Ultra-15 centrifugal unit (EMD Millipore) and flash frozen in liquid nitrogen before storage at −80°C.</p><p>Protein used during crystallography experiments was generated via the same <italic>frmB</italic> and <italic>gloB</italic> sequences, but expression was performed from vector pET28a. <italic>frmB</italic> was cloned into the pET28a vector by GeneWiz Inc (Beijing, China), and <italic>gloB</italic> was cloned from the BG1861 vector using the forward primer 5′- <named-content content-type="sequence">dTGCTCGAGTGCGGCCGCTTAACCGTGTAAAAATGGATTT-3′</named-content> and the reverse primer 5′-<named-content content-type="sequence">dCGCGCGGCAGCCATATGATGAGGATTTCAAGCTTAACTTT-</named-content>3′. The PCR product was cloned into pET28a digested with restriction enzymes NotI and NdeI using InFusion HD Cloning (Takara Bio). Both cloning strategies introduce a hexahistidine tag followed by a thrombin cleavage sequence. The pET28a plasmids encoding either frmB or gloB were transformed into chemically competent <italic>E. coli</italic> BL21(DE3) cells. Protein expression of FrmB proceeded as previously described, except FrmB containing cells were grown in Terrific Broth medium (24 g/L yeast extract, 20 g/L tryptone, 4 mL/L glycerol, 17 mM KH<sub>2</sub>PO<sub>4</sub>, 72 mM K<sub>2</sub>HPO<sub>4</sub>).</p><p>Selenomethionine (SeMet)-labeled GloB was prepared according to <xref ref-type="bibr" rid="bib53">Van Duyne et al., 1993</xref> with minor modifications . Briefly, overnight cultures were grown in LB media, washed, and resuspended in M9 minimal media (per liter: 64 g Na<sub>2</sub>HPO<sub>4</sub>, 15 g KH<sub>2</sub>PO<sub>4</sub>, 2.5 g NaCl, and 5 g NH<sub>4</sub>Cl) supplemented with 50 mg EDTA, 8 mg FeCl<sub>3</sub>, 0.5 mg ZnCl<sub>2</sub>, 0.1 mg CuCl<sub>2</sub>, 0.1 mg CoCl<sub>2</sub>, 0.1 mg H<sub>3</sub>BO<sub>3</sub>, 16 mg MnCl<sub>2</sub>, 0.1 mg Ni<sub>2</sub>SO<sub>4</sub>, 0.1 mg molybdic acid, 0.5 mg riboflavin, 0.5 mg niacinamide, 0.5 mg pyridoxine monohydrate, and 0.5 mg thiamine per liter. Resuspended cultures were grown overnight. The following day, cultures were back diluted 1:50 and grown to an OD<sub>600</sub> of 0.5–0.8 at 37°C. Once at the appropriate OD<sub>600 nm</sub>, the following amino acids were added to the culture media at: 100 mg/L: lysine, phenylalanine, and threonine, 50 mg/L: isoleucine, leucine, and valine, 60 mg/L: SeMet. Cultures were grown for an additional 15 min at 37°C before cells were chilled to 16°C and induced with 0.5 mM IPTG for 16–20 hr.</p><p>Protein purification of FrmB- and SeMet-labeled GloB for crystallography proceeded as previously except following affinity purification the elution was dialyzed for 16–20 hr at 4°C with 20 U thrombin protease (GE Healthsciences) to remove the hexahistidine tag. Dialysis buffer contained 50 mM Tris pH 7.5, 50 mM NaCl, and 1 mM MgCl<sub>2</sub>. Following dialysis, uncleaved protein, the hexahistidine tag, and thrombin were removed by flowing dialyzed protein over a benzamidine sepharose and nickel agarose bead column (GE Healthsciences). Column flow through was further purified over a HiLoad 16/60 Superdex-200 gel filtration column (GE Healthsciences) equilibrated with dialysis buffer. Protein was concentrated to 8–10 mg/mL in an Amicon Ultra-15 centrifugal unit and frozen at −80°C.</p></sec><sec id="s4-8"><title>Glyoxalase II activity assay</title><p>Glyoxalase II activity was assessed as previously with minor changes (<xref ref-type="bibr" rid="bib41">Mikati et al., 2020</xref>; <xref ref-type="bibr" rid="bib49">Stamp et al., 2010</xref>). Briefly, reactions were mixed to form a final concentration of 25 mM Tris pH 7.5, 250 mM NaCl, 1 mM MnCl<sub>2</sub>, 10% glycerol, 200 µM 5,5’-dithiobis(2-nitrobenzoic acid) (DTNB, Sigma D8130), 1 mM <sc>d</sc>-lactoylglutathione (Sigma L7140), and 0.15–0.63 µg protein (130–550 nM GloB, 100–430 nM FrmB). Protein concentrations were varied to ensure the reaction was linear across protein concentrations. Reactions without <sc>d</sc>-lactoylglutathione were pre-incubated at 37°C for 10 min prior to assay initiation with the addition of substrate. Release of glutathione from <sc>d</sc>-lactoylglutathione was quantified spectrophotometrically at 37°C and 412 nm through the conversion of DTNB to TNB. Experiments were performed in triplicate with technical duplicates.</p></sec><sec id="s4-9"><title>4-Nitrophenyl ester substrate activity assays</title><p>4-Nitrophenyl substrate-specific activity was determined in 50 µL reactions containing 25 mM Tris pH 7.5, 250 mM NaCl, 1 mM MnCl<sub>2</sub>, 10% glycerol, 1 µM protein, and 1 mM 4-nitrophenyl substrate. The tested substrates, 4-nitrophenyl acetate (Sigma, N8130), 4-nitrophenyl butyrate (Sigma N9876), and 4-nitrophenyl trimethylacetate (Sigma 135046), were resuspended in acetonitrile at 100 mM. Reactions without 4-nitrophenyl substrate were preincubated at 37°C for 10 min prior to assay initiation via substrate addition. Conversion of 4-nitrophenyl substrates to 4-nitrophenol was tracked photometrically at 37°C and A<sub>405nm</sub>. Experiments were performed in triplicate with technical duplicates.</p></sec><sec id="s4-10"><title>NMR characterization of GloB and FrmB activation products</title><p>Two hundred or 400 µM POM-HEX was incubated with 4 nmol GloB, FrmB, or 4 nmol each GloB and FrmB in 500 µL reactions. Reactions were buffered to a final concentration of 50 mM Tris pH 7.5, 50 mM NaCl, 1 mM MgCl<sub>2</sub>. Reactions were allowed to proceed for 1 hr at 37°C prior to analysis. Samples were prepared for NMR studies by resuspending them in water and 10% (50 µL) D<sub>2</sub>O (deuterium oxide 99.9% D, contains 0.75 wt% 3-(trimethylsilyl)propionic-2,2,3,3-d<sub>4</sub> acid, sodium salt, Sigma–Aldrich). NMR spectra are acquired on a Bruker Avance III HD 500 MHz spectrometer equipped with a cryoprobe. Two-dimensional (2D) <sup>1</sup>H-<sup>31</sup>P HSQC measurements were obtained using hsqcetgp pulse program (with duration of 15 min and scan parameters of two scans, td = 1024 and 256, gpz2 % = 32.40, <sup>31</sup>P SW = 40 ppm, O2p = 20 ppm, cnst2 = 22.95) and analyzed using 3.1 TopSpin. The 1D projection of columns excluding the water signal was obtained from the 2D <sup>1</sup>H-<sup>31</sup>P HSQC spectrum by obtaining spectra of positive projection of columns 1–600 and 650–1024 and adding them.</p></sec><sec id="s4-11"><title>Esterase substrate specificity determination using fluorogenic SAR library</title><p>Kinetic measurements were performed according to <xref ref-type="bibr" rid="bib56">White et al., 2018</xref> with minor variation. Lyophilized human and mouse sera were resuspended according to manufacturer instructions in highly pure, filtered water at protein concentrations of 85 mg/mL and 70 mg/mL, respectively. One milliliter of resuspended serum was added to a 24 mL mastermix for a final concentration of 31.25 mM Tris pH 7.5, 312.5 mM NaCl, 1.25 mM MgCl<sub>2</sub>, 12.5% glycerol, and 3.4 mg/mL or 2.8 mg/mL protein for human and mouse serum, respectively. For purified proteins, 5 mL of a 75 µg/mL stock was added to yield a 20 mL mastermix containing 31.25 mM Tris pH 7.5, 312.5 mM NaCl, 1.25 mM MgCl<sub>2</sub>, 12.5% glycerol, and 18.75 µg/mL protein. Mastermix was stored on ice when not in use. Twenty microliters of mastermix was transferred to a black, 96-well half area microplate (Corning, CLS3993) and prewarmed at 37°C. Fluorogenic substrates were prepared as 10 mM stock solutions in 100% DMSO and were diluted in water to a starting concentration of 500 µM. Enzyme catalyzed substrate hydrolysis was initiated by addition of 5 µL substrate dilution in technical duplicate to the prewarmed serum or protein solution. Final assay concentrations were as follows: 25 mM Tris pH 7.5, 250 mM NaCl, 1 mM MgCl<sub>2</sub>, 10% glycerol, and protein at a concentration of 2.72 mg/mL (human serum), 2.24 mg/mL (mouse serum), or 15 µg/mL (FrmB, GloB). The resulting change in fluorescence (λ<sub>ex</sub> = 485 nm, λ<sub>em</sub> = 520 nm) was followed for 15 min at 37°C, collecting data every 30 s on a FLUOstar Omega microplate reader (BMG Labtech). Fluorescence measurements were converted to molar concentrations using a fluorescein standard curve (2.5 nmol–0.6 pmol). The initial rates of reaction were measured three independent times with two technical replicates per measurement and fit to a line using GraphPad Prism (GraphPad Software, La Jolla, CA). Initial rates of reaction were plotted versus the concentration of substrate and fit to a standard Michaelis–Menten equation (<italic>v</italic> = <italic>V</italic><sub>max</sub>[S]/(<italic>K</italic><sub>m</sub> + [S])), yielding estimates of <italic>V</italic><sub>max</sub> and <italic>K</italic><sub>m</sub>. Values for <italic>k</italic><sub>cat</sub> and <italic>k</italic><sub>cat</sub>/<italic>K</italic><sub>m</sub> were calculated based on amount of enzyme added when purified enzymes were used. For substrates that did not display saturation in the velocity versus substrate experiment (i.e., <italic>K</italic><sub>m</sub>&gt;&gt;&gt;[S]), <italic>V</italic><sub>max</sub>/<italic>K</italic><sub>m</sub> was estimated based on v/[S].</p></sec><sec id="s4-12"><title>Fresh human serum</title><p>Fresh human serum was collected from a willing volunteer in untreated BD vacutainer tubes (BD, BD366430) (Washington University IRB # 201012782). Whole blood was allowed to clot at room temperature, and aggregates were separated from the remaining serum through centrifugation at 400 × g for 8 min. Sera were obtained from the same volunteer on two separate occasions.</p></sec><sec id="s4-13"><title>Serum half-life determination</title><p>Lyophilized human sera was obtained from Rockland Inc and resuspended in pure water. Twenty microliters lyophilized sera or fresh sera was prewarmed at 37°C in a 96-well half-area microplate (Corning, CLS3993). Following plate warming, 5 µL of the fluorogenic substrates were added to the plate for a final concentration of 25 µM. Substrate hydrolysis was tracked over a period of three h at 37°C, with fluorescence measurements (λ<sub>ex</sub> = 485 nm, λ<sub>em</sub> = 520 nm) being taken every two min on a FLUOstar Omega microplate reader (BMG Labtech). The resulting fluorescence values were converted to % substrate hydrolyzed using a fluorescein standard curve and fit to a one-phase decay model using GraphPad Prism. Experiments were performed in technical and biological duplicate.</p></sec><sec id="s4-14"><title>Microfluidics measurements on <italic>S. aureus</italic></title><p>Overnight cultures of <italic>S. aureus</italic> were grown in LB media, back diluted 1:500, and grown to early exponential phase (OD<sub>600 </sub>0.1–0.15), then washed in 1× PBS, and loaded on a bacterial CellASIC ONIX2 microfluidic plate. Prior to cell loading, the microfluidics plate lines were flushed with 1× PBS + 1% DMSO or 10 µM fluorescent pro-substrate in 1× PBS + 1% DMSO, and the plate was preincubated at 37°C. The microfluidics plate was loaded onto a Nikon Ti-E inverted microscope (Nikon Instruments, Inc) equipped with a 100× Plan N (N.A. = 1.45) Ph3 objective, SOLA SE Light Engine (Lumencor), heated control chamber (OKO Labs), and an ORCA-Flash4.0 sCMOS camera (Hammamatsu Photonics). The GFP filter set was purchased from Chroma Technology Corporation. Cells were loaded into the chamber until a single field of view contained 50–150 cells or cell clusters. Following cell loading, 1× PBS was slowly flown through the flow cell (t = 0), and cells were observed in both phase and fluorescence microscopy for 10 min before the flow media was rapidly switched over a period of two min to 1× PBS containing 1% DMSO and 10 µM fluorescent prosubstrate before slow flow for the remainder of the experiment. Images were acquired every two min for a total of 44 min, and all experiments were undertaken at 37°C. The phase-contrast exposure time was kept constant at 200 ms, and the fluorescent channel exposure time was kept constant at 500 ms. For fluorescent images, the gain remained constant across all experiments. Image capture and analysis was performed using Nikon Elements Advanced Research software. Individual cells or clusters of cells were auto detected in the fluorescent channel using the intrinsic background fluorescence of each cell. Manual curation followed autodetection to remove debris or cells that did not stay within the field of view throughout the experiment. Fluorescent intensity for each individual cell or cluster of cells was measured through the duration of the experiment and normalized to the area of the identified cell to yield the mean fluorescent intensity. Background cell autofluorescence was corrected by subtracting the average fluorescence across all identified objects from t = 0 through t = 10. Each experiment was performed in duplicate, with &gt;50 individual cells or clusters analyzed in each experiment.</p></sec><sec id="s4-15"><title>Protein crystallography, phasing, and data refinement</title><p>Crystals of <italic>S. aureus</italic> FrmB were grown at 16°C using vapor diffusion in 20 µL hanging drops containing a 1:1 mixture of protein (6 mg/mL) and crystallization buffer (0.1 M Tricine pH 7.7, 15% PEG6K, 2.5 M NaCl, 0.125% <italic>n</italic>-dodecyl-β-D-glucoside). Prior to data collection, crystals were stabilized in cryoprotectant (mother liquor supplemented with 20% glycerol) before flash freezing in liquid nitrogen for data collection at 100 K. Crystals of Se-Met-labeled <italic>S. aureus</italic> GloB were grown at 16°C using vapor diffusion in 2 µL hanging drops containing a 1:1 mixture of protein (8 mg/mL) and crystallization buffer (0.1 M imidazole pH 6.9, 0.2 M ammonium sulfate, 0.1 M calcium chloride, and 21% PEG 8 k). SeMet-labeled GloB crystals were stabilized in well solution supplemented with 15% glycerol and flash frozen in liquid nitrogen. All diffraction images were collected at beamline 19-ID of the Argonne National Laboratory Advanced Photon Source at Argonne National Laboratory. HKL3000 was used to index, integrate, and scale the data sets (<xref ref-type="bibr" rid="bib42">Minor et al., 2006</xref>). To phase the initial dataset of FrmB, molecular replacement was performed in PHASER using the x-ray crystal structure of a low-temperature active alkaline esterase (PDB ID: 4RGY) as a search model (<xref ref-type="bibr" rid="bib25">Hu et al., 2015</xref>; <xref ref-type="bibr" rid="bib38">McCoy et al., 2007</xref>). SeMet-labeled GloB was phased using the x-ray crystal structure of TTHA1623 from <italic>Thermus thermophilus</italic> HB8 (PDB ID: 2ZWR) (<xref ref-type="bibr" rid="bib61">Yamamura et al., 2009</xref>). Buccaneer was used to build both initial models, and subsequent, iterative rounds of model building and refinement used COOT and PHENIX, respectively (<xref ref-type="bibr" rid="bib1">Adams et al., 2010</xref>; <xref ref-type="bibr" rid="bib8">Cowtan, 2006</xref>; <xref ref-type="bibr" rid="bib11">Emsley and Cowtan, 2004</xref>). Data collection and refinement statistics are summarized in <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref> and <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>. Atomic coordinates and structure factors of <italic>S.</italic> aureus FrmB (PDB: 7L0A) and <italic>S. aureus</italic> GloB (PDB: 7L0B) are deposited in the RCSB Protein Data Bank.</p></sec><sec id="s4-16"><title>Substrate docking</title><p>GloB and FrmB structures were prepared for substrate autodocking using AutoDock Tools 1.5.7 (<xref ref-type="bibr" rid="bib43">Morris et al., 2009</xref>). Metals and water molecules were removed from the crystal structure of FrmB as canonical serine hydrolases do not utilize metal in their reaction mechanism. Solvent water in the GloB crystal structure was removed, but the active site water and heavily coordinated zinc molecules were left in place. The three-dimensional structure of substrate 1O was generated using ChemDraw3D and prepared for docking using AutoDock Tools 1.5.7. Substrate docking of FrmB and GloB was performed using AutoDock Vina (<xref ref-type="bibr" rid="bib50">Trott and Olson, 2010</xref>).</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We are grateful to the students of the Spring 2020 Biol 4522 course at Washington University for the creation of FrmB point mutation plasmids and the purification of FrmB point mutants. Thank you to Vandna Kukshal and Jason Schaffer for helpful discussions around data and mechanisms, to the Bubeck-Wardenburg laboratory for sharing benchspace during revisions, and to Petra Levin for assistance with microfluidics and microscopy. Fluorescent ester compounds were generously provided by the laboratory of Geoffrey Hoops (Butler University). AOJ is supported by NIH/NIAID R01-AI103280, R21-AI123808, and R21-AI130584, and AOJ is an Investigator in the Pathogenesis of Infectious Diseases (PATH) of the Burroughs Wellcome Fund. This publication was made possible in part by Grant Number UL1 RR024992 from the NIH-National Center for Research Resources (NCRR).</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Investigation, Visualization, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con5"><p>Formal analysis, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con6"><p>Formal analysis, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Writing - review and editing</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Funding acquisition, Writing - review and editing</p></fn><fn fn-type="con" id="con9"><p>Formal analysis, Supervision, Writing - review and editing</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Supervision, Funding acquisition, Writing - review and editing</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Supervision, Funding acquisition, Writing - original draft, Project administration</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Resources, Formal analysis, Supervision, Funding acquisition, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Primers used during this study.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-66657-supp1-v2.docx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-66657-transrepform-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>Sequencing data and structure data is provided in the manuscript and deposited on the NCBI BioProject database (PRJNA648156) or in the protein data bank (FrmB accession code 7L0A, GloB accession code 7L0B).</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>John</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Understanding Staphylococcus aureus resistance to POM-HEX</data-title><source>NCBI BioProject</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA648156">PRJNA648156</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname> <given-names>PD</given-names></name><name><surname>Afonine</surname> <given-names>PV</given-names></name><name><surname>Bunkóczi</surname> <given-names>G</given-names></name><name><surname>Chen</surname> <given-names>VB</given-names></name><name><surname>Davis</surname> <given-names>IW</given-names></name><name><surname>Echols</surname> <given-names>N</given-names></name><name><surname>Headd</surname> <given-names>JJ</given-names></name><name><surname>Hung</surname> <given-names>LW</given-names></name><name><surname>Kapral</surname> <given-names>GJ</given-names></name><name><surname>Grosse-Kunstleve</surname> <given-names>RW</given-names></name><name><surname>McCoy</surname> <given-names>AJ</given-names></name><name><surname>Moriarty</surname> <given-names>NW</given-names></name><name><surname>Oeffner</surname> <given-names>R</given-names></name><name><surname>Read</surname> <given-names>RJ</given-names></name><name><surname>Richardson</surname> <given-names>DC</given-names></name><name><surname>Richardson</surname> <given-names>JS</given-names></name><name><surname>Terwilliger</surname> <given-names>TC</given-names></name><name><surname>Zwart</surname> <given-names>PH</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>PHENIX: a comprehensive Python-based system for macromolecular structure solution</article-title><source>Acta Crystallographica Section D Biological Crystallography</source><volume>66</volume><fpage>213</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1107/S0907444909052925</pub-id><pub-id pub-id-type="pmid">20124702</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexandrov</surname> <given-names>A</given-names></name><name><surname>Vignali</surname> <given-names>M</given-names></name><name><surname>LaCount</surname> <given-names>DJ</given-names></name><name><surname>Quartley</surname> <given-names>E</given-names></name><name><surname>de Vries</surname> <given-names>C</given-names></name><name><surname>De Rosa</surname> <given-names>D</given-names></name><name><surname>Babulski</surname> <given-names>J</given-names></name><name><surname>Mitchell</surname> <given-names>SF</given-names></name><name><surname>Schoenfeld</surname> <given-names>LW</given-names></name><name><surname>Fields</surname> <given-names>S</given-names></name><name><surname>Hol</surname> <given-names>WG</given-names></name><name><surname>Dumont</surname> <given-names>ME</given-names></name><name><surname>Phizicky</surname> <given-names>EM</given-names></name><name><surname>Grayhack</surname> <given-names>EJ</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>A facile method for high-throughput co-expression of protein pairs</article-title><source>Molecular &amp; Cellular Proteomics</source><volume>3</volume><fpage>934</fpage><lpage>938</lpage><pub-id pub-id-type="doi">10.1074/mcp.T400008-MCP200</pub-id><pub-id pub-id-type="pmid">15240823</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Antimicrobial resistance in the age of COVID-19</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Antimicrobial resistance in the age of COVID-19</article-title><source>Nature Microbiology</source><volume>5</volume><elocation-id>779</elocation-id><pub-id pub-id-type="doi">10.1038/s41564-020-0739-4</pub-id><pub-id pub-id-type="pmid">32433531</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azema</surname> <given-names>L</given-names></name><name><surname>Baron</surname> <given-names>R</given-names></name><name><surname>Ladame</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Targeting enzymes with phosphonate-based inhibitors: mimics of tetrahedral transition states and stable isosteric analogues of phosphates</article-title><source>Current enzyme inhibition</source><volume>2</volume><fpage>61</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.2174/157340806775473526</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cameron</surname> <given-names>AD</given-names></name><name><surname>Ridderström</surname> <given-names>M</given-names></name><name><surname>Olin</surname> <given-names>B</given-names></name><name><surname>Mannervik</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Crystal structure of human glyoxalase II and its complex with a glutathione thiolester substrate analogue</article-title><source>Structure</source><volume>7</volume><fpage>1067</fpage><lpage>1078</lpage><pub-id pub-id-type="doi">10.1016/S0969-2126(99)80174-9</pub-id><pub-id pub-id-type="pmid">10508780</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="software"><person-group person-group-type="author"><collab>CDC</collab></person-group><year iso-8601-date="2019">2019</year><source>Antibiotic Resistance Threats in the United States 2019</source></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cingolani</surname> <given-names>P</given-names></name><name><surname>Platts</surname> <given-names>A</given-names></name><name><surname>Wang</surname> <given-names>leL</given-names></name><name><surname>Coon</surname> <given-names>M</given-names></name><name><surname>Nguyen</surname> <given-names>T</given-names></name><name><surname>Wang</surname> <given-names>L</given-names></name><name><surname>Land</surname> <given-names>SJ</given-names></name><name><surname>Lu</surname> <given-names>X</given-names></name><name><surname>Ruden</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A program for annotating and predicting the effects of single Nucleotide Polymorphisms, SnpEff: snps in the genome of <italic>Drosophila melanogaster</italic> strain w1118; iso-2; iso-3</article-title><source>Fly</source><volume>6</volume><fpage>80</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.4161/fly.19695</pub-id><pub-id pub-id-type="pmid">22728672</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cowtan</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The buccaneer software for automated model building</article-title><source>Tracing Protein Chains. Acta Crystallogr Sect D Biol Crystallogr</source><volume>62</volume><fpage>1002</fpage><lpage>1011</lpage><pub-id pub-id-type="doi">10.1107/S0907444906022116</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname> <given-names>RL</given-names></name><name><surname>Brothers</surname> <given-names>RC</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Maron</surname> <given-names>MI</given-names></name><name><surname>Ziniel</surname> <given-names>PD</given-names></name><name><surname>Tsang</surname> <given-names>PS</given-names></name><name><surname>Kraft</surname> <given-names>TE</given-names></name><name><surname>Hruz</surname> <given-names>PW</given-names></name><name><surname>Williamson</surname> <given-names>KC</given-names></name><name><surname>Dowd</surname> <given-names>CS</given-names></name><name><surname>John</surname> <given-names>ARO</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>MEPicides: potent antimalarial prodrugs targeting isoprenoid biosynthesis</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>8400</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-07159-y</pub-id><pub-id pub-id-type="pmid">28827774</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname> <given-names>RL</given-names></name><name><surname>Heueck</surname> <given-names>I</given-names></name><name><surname>Lee</surname> <given-names>SG</given-names></name><name><surname>Shah</surname> <given-names>IT</given-names></name><name><surname>Miller</surname> <given-names>JJ</given-names></name><name><surname>Jezewski</surname> <given-names>AJ</given-names></name><name><surname>Mikati</surname> <given-names>MO</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Brothers</surname> <given-names>RC</given-names></name><name><surname>Heidel</surname> <given-names>KM</given-names></name><name><surname>Osbourn</surname> <given-names>DM</given-names></name><name><surname>Burnham</surname> <given-names>CD</given-names></name><name><surname>Alvarez</surname> <given-names>S</given-names></name><name><surname>Fritz</surname> <given-names>SA</given-names></name><name><surname>Dowd</surname> <given-names>CS</given-names></name><name><surname>Jez</surname> <given-names>JM</given-names></name><name><surname>Odom John</surname> <given-names>AR</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Potent, specific MEPicides for treatment of zoonotic staphylococci</article-title><source>PLOS Pathogens</source><volume>16</volume><elocation-id>e1007806</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1007806</pub-id><pub-id pub-id-type="pmid">32497104</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emsley</surname> <given-names>P</given-names></name><name><surname>Cowtan</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Coot: model-building tools for molecular graphics</article-title><source>Acta Crystallographica. Section D, Biological Crystallography</source><volume>60</volume><fpage>2126</fpage><lpage>2132</lpage><pub-id pub-id-type="doi">10.1107/S0907444904019158</pub-id><pub-id pub-id-type="pmid">15572765</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erion</surname> <given-names>MD</given-names></name><name><surname>Reddy</surname> <given-names>KR</given-names></name><name><surname>Boyer</surname> <given-names>SH</given-names></name><name><surname>Matelich</surname> <given-names>MC</given-names></name><name><surname>Gomez-Galeno</surname> <given-names>J</given-names></name><name><surname>Lemus</surname> <given-names>RH</given-names></name><name><surname>Ugarkar</surname> <given-names>BG</given-names></name><name><surname>Colby</surname> <given-names>TJ</given-names></name><name><surname>Schanzer</surname> <given-names>J</given-names></name><name><surname>Van Poelje</surname> <given-names>PD</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Design, synthesis, and characterization of a series of cytochrome P(450) 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver</article-title><source>Journal of the American Chemical Society</source><volume>126</volume><fpage>5154</fpage><lpage>5163</lpage><pub-id pub-id-type="doi">10.1021/ja031818y</pub-id><pub-id pub-id-type="pmid">15099098</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erion</surname> <given-names>MD</given-names></name><name><surname>van Poelje</surname> <given-names>PD</given-names></name><name><surname>MacKenna</surname> <given-names>DA</given-names></name><name><surname>Colby</surname> <given-names>TJ</given-names></name><name><surname>Montag</surname> <given-names>AC</given-names></name><name><surname>Fujitaki</surname> <given-names>JM</given-names></name><name><surname>Linemeyer</surname> <given-names>DL</given-names></name><name><surname>Bullough</surname> <given-names>DA</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Liver-Targeted drug delivery using HepDirect prodrugs</article-title><source>Journal of Pharmacology and Experimental Therapeutics</source><volume>312</volume><fpage>554</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1124/jpet.104.075903</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the ES of CM and ID (ESCMID)</collab></person-group><year iso-8601-date="2000">2000</year><article-title>Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by agar dilution</article-title><source>Clinical Microbiology and Infection</source><volume>6</volume><fpage>509</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1046/j.1469-0691.2000.00142.x</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fellner</surname> <given-names>M</given-names></name><name><surname>Lentz</surname> <given-names>CS</given-names></name><name><surname>Jamieson</surname> <given-names>SA</given-names></name><name><surname>Brewster</surname> <given-names>JL</given-names></name><name><surname>Chen</surname> <given-names>L</given-names></name><name><surname>Bogyo</surname> <given-names>M</given-names></name><name><surname>Mace</surname> <given-names>PD</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structural basis for the inhibitor and substrate specificity of the unique fph serine hydrolases of <italic>Staphylococcus aureus</italic></article-title><source>ACS Infectious Diseases</source><volume>6</volume><fpage>2771</fpage><lpage>2782</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.0c00503</pub-id><pub-id pub-id-type="pmid">32865965</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fey</surname> <given-names>PD</given-names></name><name><surname>Endres</surname> <given-names>JL</given-names></name><name><surname>Yajjala</surname> <given-names>VK</given-names></name><name><surname>Widhelm</surname> <given-names>TJ</given-names></name><name><surname>Boissy</surname> <given-names>RJ</given-names></name><name><surname>Bose</surname> <given-names>JL</given-names></name><name><surname>Bayles</surname> <given-names>KW</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>A genetic resource for rapid and comprehensive phenotype screening of nonessential <italic>Staphylococcus aureus</italic> genes</article-title><source>mBio</source><volume>4</volume><elocation-id>e00537-12</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.00537-12</pub-id><pub-id pub-id-type="pmid">23404398</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Fuchs</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2007">2007</year><source>Case Study: Cefditoren Pivoxil: An Oral Prodrug of CefditorenProdrugs</source><publisher-name>Springer</publisher-name></element-citation></ref><ref id="bib18"><element-citation publication-type="software"><person-group person-group-type="author"><collab>Global Antimicrobial Resistance Hub</collab></person-group><year iso-8601-date="2020">2020</year><source>Global Antimicrobial Resistance Hub</source><ext-link ext-link-type="uri" xlink:href="https://dashboard.globalamrhub.org/reports/pipelines/pipelines">https://dashboard.globalamrhub.org/reports/pipelines/pipelines</ext-link></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez</surname> <given-names>CF</given-names></name><name><surname>Proudfoot</surname> <given-names>M</given-names></name><name><surname>Brown</surname> <given-names>G</given-names></name><name><surname>Korniyenko</surname> <given-names>Y</given-names></name><name><surname>Mori</surname> <given-names>H</given-names></name><name><surname>Savchenko</surname> <given-names>AV</given-names></name><name><surname>Yakunin</surname> <given-names>AF</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Molecular basis of formaldehyde detoxification characterization of two S-formylglutathione hydrolases from <italic>Escherichia coli</italic>, FrmB and YeiG</article-title><source>The Journal of Biological Chemistry</source><volume>281</volume><fpage>14514</fpage><lpage>14522</lpage><pub-id pub-id-type="doi">10.1074/jbc.M600996200</pub-id><pub-id pub-id-type="pmid">16567800</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hecker</surname> <given-names>SJ</given-names></name><name><surname>Erion</surname> <given-names>MD</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Prodrugs of phosphates and phosphonates</article-title><source>Journal of Medicinal Chemistry</source><volume>51</volume><fpage>2328</fpage><lpage>2345</lpage><pub-id pub-id-type="doi">10.1021/jm701260b</pub-id><pub-id pub-id-type="pmid">18237108</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heidel</surname> <given-names>KM</given-names></name><name><surname>Dowd</surname> <given-names>CS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Phosphonate prodrugs: an overview and recent advances</article-title><source>Future Medicinal Chemistry</source><volume>11</volume><fpage>1625</fpage><lpage>1643</lpage><pub-id pub-id-type="doi">10.4155/fmc-2018-0591</pub-id><pub-id pub-id-type="pmid">31469328</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honek</surname> <given-names>JF</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Glyoxalase biochemistry</article-title><source>Biomolecular Concepts</source><volume>6</volume><fpage>401</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1515/bmc-2015-0025</pub-id><pub-id pub-id-type="pmid">26552067</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsiao</surname> <given-names>CH</given-names></name><name><surname>Lin</surname> <given-names>X</given-names></name><name><surname>Barney</surname> <given-names>RJ</given-names></name><name><surname>Shippy</surname> <given-names>RR</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Vinogradova</surname> <given-names>O</given-names></name><name><surname>Wiemer</surname> <given-names>DF</given-names></name><name><surname>Wiemer</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Synthesis of a phosphoantigen prodrug that potently activates Vγ9Vδ2 T-lymphocytes</article-title><source>Chemistry &amp; Biology</source><volume>21</volume><fpage>945</fpage><lpage>954</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2014.06.006</pub-id><pub-id pub-id-type="pmid">25065532</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>How covid-19 is accelerating the threat of antimicrobial resistance</article-title><source>BMJ</source><volume>369</volume><elocation-id>m1983</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.m1983</pub-id><pub-id pub-id-type="pmid">32423901</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname> <given-names>Y</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Feng</surname> <given-names>Y</given-names></name><name><surname>Lu</surname> <given-names>N</given-names></name><name><surname>Zhu</surname> <given-names>B</given-names></name><name><surname>Xue</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Structural and functional analysis of a low-temperature-active alkaline esterase from South China Sea marine sediment microbial metagenomic library</article-title><source>Journal of Industrial Microbiology and Biotechnology</source><volume>42</volume><fpage>1449</fpage><lpage>1461</lpage><pub-id pub-id-type="doi">10.1007/s10295-015-1653-2</pub-id><pub-id pub-id-type="pmid">26350078</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>MH</given-names></name><name><surname>Kang</surname> <given-names>BS</given-names></name><name><surname>Kim</surname> <given-names>S</given-names></name><name><surname>Kim</surname> <given-names>K-J</given-names></name><name><surname>Lee</surname> <given-names>CH</given-names></name><name><surname>Oh</surname> <given-names>B-C</given-names></name><name><surname>Park</surname> <given-names>S-C</given-names></name><name><surname>Oh</surname> <given-names>T-K</given-names></name><name><surname>B-c</surname> <given-names>O</given-names></name><name><surname>T-k</surname> <given-names>O</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The crystal structure of the estA protein, a virulence factor from <italic>Streptococcus pneumoniae</italic></article-title><source>Proteins: Structure, Function, and Bioinformatics</source><volume>70</volume><fpage>578</fpage><lpage>583</lpage><pub-id pub-id-type="doi">10.1002/prot.21680</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kornberg</surname> <given-names>RD</given-names></name><name><surname>McNamee</surname> <given-names>MG</given-names></name><name><surname>McConnell</surname> <given-names>HM</given-names></name></person-group><year iso-8601-date="1972">1972</year><article-title>Measurement of transmembrane potentials in phospholipid vesicles</article-title><source>PNAS</source><volume>69</volume><fpage>1508</fpage><lpage>1513</lpage><pub-id pub-id-type="doi">10.1073/pnas.69.6.1508</pub-id><pub-id pub-id-type="pmid">4338594</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kourtis</surname> <given-names>AP</given-names></name><name><surname>Hatfield</surname> <given-names>K</given-names></name><name><surname>Baggs</surname> <given-names>J</given-names></name><name><surname>Mu</surname> <given-names>Y</given-names></name><name><surname>See</surname> <given-names>I</given-names></name><name><surname>Epson</surname> <given-names>E</given-names></name><name><surname>Nadle</surname> <given-names>J</given-names></name><name><surname>Kainer</surname> <given-names>MA</given-names></name><name><surname>Dumyati</surname> <given-names>G</given-names></name><name><surname>Petit</surname> <given-names>S</given-names></name><name><surname>Ray</surname> <given-names>SM</given-names></name><name><surname>Ham</surname> <given-names>D</given-names></name><name><surname>Capers</surname> <given-names>C</given-names></name><name><surname>Ewing</surname> <given-names>H</given-names></name><name><surname>Coffin</surname> <given-names>N</given-names></name><name><surname>McDonald</surname> <given-names>LC</given-names></name><name><surname>Jernigan</surname> <given-names>J</given-names></name><name><surname>Cardo</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title><italic>Vital Signs:</italic> Epidemiology and Recent Trends in Methicillin-Resistant and in Methicillin-Susceptible <italic>Staphylococcus aureus</italic> Bloodstream Infections — United States</article-title><source>MMWR. Morbidity and Mortality Weekly Report</source><volume>68</volume><fpage>214</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm6809e1</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laizure</surname> <given-names>SC</given-names></name><name><surname>Herring</surname> <given-names>V</given-names></name><name><surname>Hu</surname> <given-names>Z</given-names></name><name><surname>Witbrodt</surname> <given-names>K</given-names></name><name><surname>Parker</surname> <given-names>RB</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The role of human carboxylesterases in drug metabolism: have we overlooked their importance?</article-title><source>Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy</source><volume>33</volume><fpage>210</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1002/phar.1194</pub-id><pub-id pub-id-type="pmid">23386599</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lentz</surname> <given-names>CS</given-names></name><name><surname>Sheldon</surname> <given-names>JR</given-names></name><name><surname>Crawford</surname> <given-names>LA</given-names></name><name><surname>Cooper</surname> <given-names>R</given-names></name><name><surname>Garland</surname> <given-names>M</given-names></name><name><surname>Amieva</surname> <given-names>MR</given-names></name><name><surname>Weerapana</surname> <given-names>E</given-names></name><name><surname>Skaar</surname> <given-names>EP</given-names></name><name><surname>Bogyo</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Identification of a <italic>S. aureus</italic> virulence factor by activity-based protein profiling (ABPP)</article-title><source>Nature Chemical Biology</source><volume>14</volume><fpage>609</fpage><lpage>617</lpage><pub-id pub-id-type="doi">10.1038/s41589-018-0060-1</pub-id><pub-id pub-id-type="pmid">29769740</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Letunic</surname> <given-names>I</given-names></name><name><surname>Bork</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Interactive Tree Of Life (iTOL) v4: recent updates and new developments</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>W256</fpage><lpage>W259</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz239</pub-id><pub-id pub-id-type="pmid">30931475</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>B</given-names></name><name><surname>Sedlacek</surname> <given-names>M</given-names></name><name><surname>Manoharan</surname> <given-names>I</given-names></name><name><surname>Boopathy</surname> <given-names>R</given-names></name><name><surname>Duysen</surname> <given-names>EG</given-names></name><name><surname>Masson</surname> <given-names>P</given-names></name><name><surname>Lockridge</surname> <given-names>O</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma</article-title><source>Biochemical Pharmacology</source><volume>70</volume><fpage>1673</fpage><lpage>1684</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2005.09.002</pub-id><pub-id pub-id-type="pmid">16213467</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Handsaker</surname> <given-names>B</given-names></name><name><surname>Wysoker</surname> <given-names>A</given-names></name><name><surname>Fennell</surname> <given-names>T</given-names></name><name><surname>Ruan</surname> <given-names>J</given-names></name><name><surname>Homer</surname> <given-names>N</given-names></name><name><surname>Marth</surname> <given-names>G</given-names></name><name><surname>Abecasis</surname> <given-names>G</given-names></name><name><surname>Durbin</surname> <given-names>R</given-names></name><collab>1000 Genome Project Data Processing Subgroup</collab></person-group><year iso-8601-date="2009">2009</year><article-title>The Sequence Alignment/Map format and SAMtools</article-title><source>Bioinformatics</source><volume>25</volume><fpage>2078</fpage><lpage>2079</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp352</pub-id><pub-id pub-id-type="pmid">19505943</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname> <given-names>YH</given-names></name><name><surname>Satani</surname> <given-names>N</given-names></name><name><surname>Hammoudi</surname> <given-names>N</given-names></name><name><surname>Yan</surname> <given-names>VC</given-names></name><name><surname>Barekatain</surname> <given-names>Y</given-names></name><name><surname>Khadka</surname> <given-names>S</given-names></name><name><surname>Ackroyd</surname> <given-names>JJ</given-names></name><name><surname>Georgiou</surname> <given-names>DK</given-names></name><name><surname>Pham</surname> <given-names>CD</given-names></name><name><surname>Arthur</surname> <given-names>K</given-names></name><name><surname>Maxwell</surname> <given-names>D</given-names></name><name><surname>Peng</surname> <given-names>Z</given-names></name><name><surname>Leonard</surname> <given-names>PG</given-names></name><name><surname>Czako</surname> <given-names>B</given-names></name><name><surname>Pisaneschi</surname> <given-names>F</given-names></name><name><surname>Mandal</surname> <given-names>P</given-names></name><name><surname>Sun</surname> <given-names>Y</given-names></name><name><surname>Zielinski</surname> <given-names>R</given-names></name><name><surname>Pando</surname> <given-names>SC</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Tran</surname> <given-names>T</given-names></name><name><surname>Xu</surname> <given-names>Q</given-names></name><name><surname>Wu</surname> <given-names>Q</given-names></name><name><surname>Jiang</surname> <given-names>Y</given-names></name><name><surname>Kang</surname> <given-names>Z</given-names></name><name><surname>Asara</surname> <given-names>JM</given-names></name><name><surname>Priebe</surname> <given-names>W</given-names></name><name><surname>Bornmann</surname> <given-names>W</given-names></name><name><surname>Marszalek</surname> <given-names>JR</given-names></name><name><surname>DePinho</surname> <given-names>RA</given-names></name><name><surname>Muller</surname> <given-names>FL</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>An enolase inhibitor for the targeted treatment of ENO1-deleted cancers</article-title><source>Nature Metabolism</source><volume>2</volume><fpage>1413</fpage><lpage>1426</lpage><pub-id pub-id-type="doi">10.1038/s42255-020-00313-3</pub-id><pub-id pub-id-type="pmid">33230295</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mackie</surname> <given-names>RS</given-names></name><name><surname>McKenney</surname> <given-names>ES</given-names></name><name><surname>van Hoek</surname> <given-names>ML</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Resistance of <italic>Francisella</italic> novicida to fosmidomycin associated with mutations in the glycerol-3-phosphate transporter</article-title><source>Frontiers in Microbiology</source><volume>3</volume><elocation-id>226</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2012.00226</pub-id><pub-id pub-id-type="pmid">22905031</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madeira</surname> <given-names>F</given-names></name><name><surname>Park</surname> <given-names>YM</given-names></name><name><surname>Lee</surname> <given-names>J</given-names></name><name><surname>Buso</surname> <given-names>N</given-names></name><name><surname>Gur</surname> <given-names>T</given-names></name><name><surname>Madhusoodanan</surname> <given-names>N</given-names></name><name><surname>Basutkar</surname> <given-names>P</given-names></name><name><surname>Tivey</surname> <given-names>ARN</given-names></name><name><surname>Potter</surname> <given-names>SC</given-names></name><name><surname>Finn</surname> <given-names>RD</given-names></name><name><surname>Lopez</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The EMBL-EBI search and sequence analysis tools APIs in 2019</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>W636</fpage><lpage>W641</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz268</pub-id><pub-id pub-id-type="pmid">30976793</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marasinghe</surname> <given-names>GP</given-names></name><name><surname>Sander</surname> <given-names>IM</given-names></name><name><surname>Bennett</surname> <given-names>B</given-names></name><name><surname>Periyannan</surname> <given-names>G</given-names></name><name><surname>Yang</surname> <given-names>KW</given-names></name><name><surname>Makaroff</surname> <given-names>CA</given-names></name><name><surname>Crowder</surname> <given-names>MW</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Structural studies on a mitochondrial glyoxalase II</article-title><source>Journal of Biological Chemistry</source><volume>280</volume><fpage>40668</fpage><lpage>40675</lpage><pub-id pub-id-type="doi">10.1074/jbc.M509748200</pub-id><pub-id pub-id-type="pmid">16227621</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCoy</surname> <given-names>AJ</given-names></name><name><surname>Grosse-Kunstleve</surname> <given-names>RW</given-names></name><name><surname>Adams</surname> <given-names>PD</given-names></name><name><surname>Winn</surname> <given-names>MD</given-names></name><name><surname>Storoni</surname> <given-names>LC</given-names></name><name><surname>Read</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Phaser crystallographic software</article-title><source>Journal of Applied Crystallography</source><volume>40</volume><fpage>658</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1107/S0021889807021206</pub-id><pub-id pub-id-type="pmid">19461840</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKenney</surname> <given-names>ES</given-names></name><name><surname>Sargent</surname> <given-names>M</given-names></name><name><surname>Khan</surname> <given-names>H</given-names></name><name><surname>Uh</surname> <given-names>E</given-names></name><name><surname>Jackson</surname> <given-names>ER</given-names></name><name><surname>San Jose</surname> <given-names>G</given-names></name><name><surname>Couch</surname> <given-names>RD</given-names></name><name><surname>Dowd</surname> <given-names>CS</given-names></name><name><surname>van Hoek</surname> <given-names>ML</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Lipophilic prodrugs of FR900098 are antimicrobial against Francisella novicida <italic>in vivo</italic> and <italic>in vitro</italic> and show GlpT independent efficacy</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e38167</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0038167</pub-id><pub-id pub-id-type="pmid">23077474</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melino</surname> <given-names>S</given-names></name><name><surname>Capo</surname> <given-names>C</given-names></name><name><surname>Dragani</surname> <given-names>B</given-names></name><name><surname>Aceto</surname> <given-names>A</given-names></name><name><surname>Petruzzelli</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>A zinc-binding motif conserved in glyoxalase II, beta-lactamase and arylsulfatases</article-title><source>Trends in Biochemical Sciences</source><volume>23</volume><fpage>381</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1016/S0968-0004(98)01264-X</pub-id><pub-id pub-id-type="pmid">9810225</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mikati</surname> <given-names>MO</given-names></name><name><surname>Miller</surname> <given-names>JJ</given-names></name><name><surname>Osbourn</surname> <given-names>DM</given-names></name><name><surname>Barekatain</surname> <given-names>Y</given-names></name><name><surname>Ghebremichael</surname> <given-names>N</given-names></name><name><surname>Shah</surname> <given-names>IT</given-names></name><name><surname>Burnham</surname> <given-names>C-AD</given-names></name><name><surname>Heidel</surname> <given-names>KM</given-names></name><name><surname>Yan</surname> <given-names>VC</given-names></name><name><surname>Muller</surname> <given-names>FL</given-names></name><name><surname>Dowd</surname> <given-names>CS</given-names></name><name><surname>Edwards</surname> <given-names>RL</given-names></name><name><surname>Odom John</surname> <given-names>AR</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Antimicrobial prodrug activation by the staphylococcal glyoxalase GloB</article-title><source>ACS Infect Dis Acsinfecdis</source><volume>11</volume><fpage>3064</fpage><lpage>3075</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.0c00582</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minor</surname> <given-names>W</given-names></name><name><surname>Cymborowski</surname> <given-names>M</given-names></name><name><surname>Otwinowski</surname> <given-names>Z</given-names></name><name><surname>Chruszcz</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title><italic>HKL</italic> -3000: the integration of data reduction and structure solution – from diffraction images to an initial model in minutes</article-title><source>Acta Crystallographica Section D Biological Crystallography</source><volume>62</volume><fpage>859</fpage><lpage>866</lpage><pub-id pub-id-type="doi">10.1107/S0907444906019949</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname> <given-names>GM</given-names></name><name><surname>Huey</surname> <given-names>R</given-names></name><name><surname>Lindstrom</surname> <given-names>W</given-names></name><name><surname>Sanner</surname> <given-names>MF</given-names></name><name><surname>Belew</surname> <given-names>RK</given-names></name><name><surname>Goodsell</surname> <given-names>DS</given-names></name><name><surname>Olson</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility</article-title><source>Journal of Computational Chemistry</source><volume>30</volume><fpage>2785</fpage><lpage>2791</lpage><pub-id pub-id-type="doi">10.1002/jcc.21256</pub-id><pub-id pub-id-type="pmid">19399780</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moustafa</surname> <given-names>AM</given-names></name><name><surname>Planet</surname> <given-names>PJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>WhatsGNU: a tool for identifying proteomic novelty</article-title><source>Genome Biology</source><volume>21</volume><elocation-id>58</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-020-01965-w</pub-id><pub-id pub-id-type="pmid">32138767</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Neill</surname> <given-names>AJ</given-names></name><name><surname>Cove</surname> <given-names>JH</given-names></name><name><surname>Chopra</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Mutation frequencies for resistance to fusidic acid and rifampicin in <italic>Staphylococcus aureus</italic></article-title><source>Journal of Antimicrobial Chemotherapy</source><volume>47</volume><fpage>647</fpage><lpage>650</lpage><pub-id pub-id-type="doi">10.1093/jac/47.5.647</pub-id><pub-id pub-id-type="pmid">11328777</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richardson</surname> <given-names>CM</given-names></name><name><surname>Nunns</surname> <given-names>CL</given-names></name><name><surname>Williamson</surname> <given-names>DS</given-names></name><name><surname>Parratt</surname> <given-names>MJ</given-names></name><name><surname>Dokurno</surname> <given-names>P</given-names></name><name><surname>Howes</surname> <given-names>R</given-names></name><name><surname>Borgognoni</surname> <given-names>J</given-names></name><name><surname>Drysdale</surname> <given-names>MJ</given-names></name><name><surname>Finch</surname> <given-names>H</given-names></name><name><surname>Hubbard</surname> <given-names>RE</given-names></name><name><surname>Jackson</surname> <given-names>PS</given-names></name><name><surname>Kierstan</surname> <given-names>P</given-names></name><name><surname>Lentzen</surname> <given-names>G</given-names></name><name><surname>Moore</surname> <given-names>JD</given-names></name><name><surname>Murray</surname> <given-names>JB</given-names></name><name><surname>Simmonite</surname> <given-names>H</given-names></name><name><surname>Surgenor</surname> <given-names>AE</given-names></name><name><surname>Torrance</surname> <given-names>CJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Discovery of a potent CDK2 inhibitor with a novel binding mode, using virtual screening and initial, structure-guided lead scoping</article-title><source>Bioorganic &amp; Medicinal Chemistry Letters</source><volume>17</volume><fpage>3880</fpage><lpage>3885</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2007.04.110</pub-id><pub-id pub-id-type="pmid">17570665</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>San Jose</surname> <given-names>G</given-names></name><name><surname>Jackson</surname> <given-names>ER</given-names></name><name><surname>Uh</surname> <given-names>E</given-names></name><name><surname>Johny</surname> <given-names>C</given-names></name><name><surname>Haymond</surname> <given-names>A</given-names></name><name><surname>Lundberg</surname> <given-names>L</given-names></name><name><surname>Pinkham</surname> <given-names>C</given-names></name><name><surname>Kehn-Hall</surname> <given-names>K</given-names></name><name><surname>Boshoff</surname> <given-names>HI</given-names></name><name><surname>Couch</surname> <given-names>RD</given-names></name><name><surname>Dowd</surname> <given-names>CS</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Design of Potential Bisubstrate Inhibitors against <italic>Mycobacterium tuberculosis</italic> (Mtb) 1-Deoxy-D-Xylulose 5-Phosphate Reductoisomerase (Dxr)-Evidence of a Novel Binding Mode</article-title><source>MedChemComm</source><volume>4</volume><fpage>1099</fpage><lpage>1104</lpage><pub-id pub-id-type="doi">10.1039/c3md00085k</pub-id><pub-id pub-id-type="pmid">23914289</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>San Jose</surname> <given-names>G</given-names></name><name><surname>Jackson</surname> <given-names>ER</given-names></name><name><surname>Haymond</surname> <given-names>A</given-names></name><name><surname>Johny</surname> <given-names>C</given-names></name><name><surname>Edwards</surname> <given-names>RL</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Brothers</surname> <given-names>RC</given-names></name><name><surname>Edelstein</surname> <given-names>EK</given-names></name><name><surname>Odom</surname> <given-names>AR</given-names></name><name><surname>Boshoff</surname> <given-names>HI</given-names></name><name><surname>Couch</surname> <given-names>RD</given-names></name><name><surname>Dowd</surname> <given-names>CS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Structure-Activity Relationships of the MEPicides: N-Acyl and O-Linked Analogs of FR900098 as Inhibitors of Dxr from <italic>Mycobacterium tuberculosis</italic> and <italic>Yersinia pestis</italic></article-title><source>ACS Infectious Diseases</source><volume>2</volume><fpage>923</fpage><lpage>935</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.6b00125</pub-id><pub-id pub-id-type="pmid">27676224</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stamp</surname> <given-names>AL</given-names></name><name><surname>Owen</surname> <given-names>P</given-names></name><name><surname>El Omari</surname> <given-names>K</given-names></name><name><surname>Nichols</surname> <given-names>CE</given-names></name><name><surname>Lockyer</surname> <given-names>M</given-names></name><name><surname>Lamb</surname> <given-names>HK</given-names></name><name><surname>Charles</surname> <given-names>IG</given-names></name><name><surname>Hawkins</surname> <given-names>AR</given-names></name><name><surname>Stammers</surname> <given-names>DK</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Structural and functional characterization of <italic>Salmonella enterica serovar</italic> Typhimurium YcbL: an unusual Type II glyoxalase</article-title><source>Protein Science</source><volume>19</volume><fpage>1897</fpage><lpage>1905</lpage><pub-id pub-id-type="doi">10.1002/pro.475</pub-id><pub-id pub-id-type="pmid">20669241</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trott</surname> <given-names>O</given-names></name><name><surname>Olson</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>AutoDock vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</article-title><source>Journal of Computational Chemistry</source><volume>31</volume><fpage>455</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1002/jcc.21334</pub-id><pub-id pub-id-type="pmid">19499576</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname> <given-names>NA</given-names></name><name><surname>Sharma-Kuinkel</surname> <given-names>BK</given-names></name><name><surname>Maskarinec</surname> <given-names>SA</given-names></name><name><surname>Eichenberger</surname> <given-names>EM</given-names></name><name><surname>Shah</surname> <given-names>PP</given-names></name><name><surname>Carugati</surname> <given-names>M</given-names></name><name><surname>Holland</surname> <given-names>TL</given-names></name><name><surname>Fowler</surname> <given-names>VG</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Methicillin-resistant <italic>Staphylococcus aureus</italic>: an overview of basic and clinical research</article-title><source>Nature Reviews Microbiology</source><volume>17</volume><fpage>203</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1038/s41579-018-0147-4</pub-id><pub-id pub-id-type="pmid">30737488</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uh</surname> <given-names>E</given-names></name><name><surname>Jackson</surname> <given-names>ER</given-names></name><name><surname>San Jose</surname> <given-names>G</given-names></name><name><surname>Maddox</surname> <given-names>M</given-names></name><name><surname>Lee</surname> <given-names>RE</given-names></name><name><surname>Lee</surname> <given-names>RE</given-names></name><name><surname>Boshoff</surname> <given-names>HI</given-names></name><name><surname>Dowd</surname> <given-names>CS</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Antibacterial and antitubercular activity of fosmidomycin, FR900098, and their lipophilic analogs</article-title><source>Bioorganic &amp; Medicinal Chemistry Letters</source><volume>21</volume><fpage>6973</fpage><lpage>6976</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2011.09.123</pub-id><pub-id pub-id-type="pmid">22024034</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Duyne</surname> <given-names>GD</given-names></name><name><surname>Standaert</surname> <given-names>RF</given-names></name><name><surname>Karplus</surname> <given-names>PA</given-names></name><name><surname>Schreiber</surname> <given-names>SL</given-names></name><name><surname>Clardy</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Atomic structures of the human immunophilin FKBP-12 complexes with FK506 and rapamycin</article-title><source>Journal of Molecular Biology</source><volume>229</volume><fpage>105</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1006/jmbi.1993.1012</pub-id><pub-id pub-id-type="pmid">7678431</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Edwards</surname> <given-names>RL</given-names></name><name><surname>Ball</surname> <given-names>H</given-names></name><name><surname>Johnson</surname> <given-names>C</given-names></name><name><surname>Haymond</surname> <given-names>A</given-names></name><name><surname>Girma</surname> <given-names>M</given-names></name><name><surname>Manikkam</surname> <given-names>M</given-names></name><name><surname>Brothers</surname> <given-names>RC</given-names></name><name><surname>McKay</surname> <given-names>KT</given-names></name><name><surname>Arnett</surname> <given-names>SD</given-names></name><name><surname>Osbourn</surname> <given-names>DM</given-names></name><name><surname>Alvarez</surname> <given-names>S</given-names></name><name><surname>Boshoff</surname> <given-names>HI</given-names></name><name><surname>Meyers</surname> <given-names>MJ</given-names></name><name><surname>Couch</surname> <given-names>RD</given-names></name><name><surname>Odom John</surname> <given-names>AR</given-names></name><name><surname>Dowd</surname> <given-names>CS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>MEPicides: α,β-Unsaturated fosmidomycin analogues as DXR inhibitors against malaria</article-title><source>Journal of Medicinal Chemistry</source><volume>61</volume><fpage>8847</fpage><lpage>8858</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.8b01026</pub-id><pub-id pub-id-type="pmid">30192536</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wefers</surname> <given-names>D</given-names></name><name><surname>Cavalcante</surname> <given-names>JJV</given-names></name><name><surname>Schendel</surname> <given-names>RR</given-names></name><name><surname>Deveryshetty</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>K</given-names></name><name><surname>Wawrzak</surname> <given-names>Z</given-names></name><name><surname>Mackie</surname> <given-names>RI</given-names></name><name><surname>Koropatkin</surname> <given-names>NM</given-names></name><name><surname>Cann</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Biochemical and structural analyses of two cryptic esterases in Bacteroides intestinalis and their synergistic activities with cognate xylanases</article-title><source>Journal of Molecular Biology</source><volume>429</volume><fpage>2509</fpage><lpage>2527</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2017.06.017</pub-id><pub-id pub-id-type="pmid">28669823</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname> <given-names>A</given-names></name><name><surname>Koelper</surname> <given-names>A</given-names></name><name><surname>Russell</surname> <given-names>A</given-names></name><name><surname>Larsen</surname> <given-names>EM</given-names></name><name><surname>Kim</surname> <given-names>C</given-names></name><name><surname>Lavis</surname> <given-names>LD</given-names></name><name><surname>Hoops</surname> <given-names>GC</given-names></name><name><surname>Johnson</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Fluorogenic structure activity library pinpoints molecular variations in substrate specificity of structurally homologous esterases</article-title><source>Journal of Biological Chemistry</source><volume>293</volume><fpage>13851</fpage><lpage>13862</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA118.003972</pub-id><pub-id pub-id-type="pmid">30006352</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="software"><person-group person-group-type="author"><collab>WHO (World Health Organisation)</collab></person-group><year iso-8601-date="2019">2019a</year><source>No Time to Wait: Securing the Future From Drug-Resistant Infections</source></element-citation></ref><ref id="bib58"><element-citation publication-type="software"><person-group person-group-type="author"><collab>WHO (World Health Organisation)</collab></person-group><year iso-8601-date="2019">2019b</year><source>Antibacterial Agents in Preclinical Development: An Open Access Database</source></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiemer</surname> <given-names>AJ</given-names></name><name><surname>Wiemer</surname> <given-names>DF</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Prodrugs of phosphonates and phosphates: crossing the membrane barrier</article-title><source>Top Curr Chem. </source><volume>200</volume><fpage>115</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1007/128_2014_561</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname> <given-names>D</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Song</surname> <given-names>G</given-names></name><name><surname>Zhang</surname> <given-names>D</given-names></name><name><surname>Shaw</surname> <given-names>N</given-names></name><name><surname>Liu</surname> <given-names>ZJ</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Crystal structure of human esterase D: a potential genetic marker of retinoblastoma</article-title><source>The FASEB Journal</source><volume>23</volume><fpage>1441</fpage><lpage>1446</lpage><pub-id pub-id-type="doi">10.1096/fj.08-125286</pub-id><pub-id pub-id-type="pmid">19126594</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamura</surname> <given-names>A</given-names></name><name><surname>Okada</surname> <given-names>A</given-names></name><name><surname>Kameda</surname> <given-names>Y</given-names></name><name><surname>Ohtsuka</surname> <given-names>J</given-names></name><name><surname>Nakagawa</surname> <given-names>N</given-names></name><name><surname>Ebihara</surname> <given-names>A</given-names></name><name><surname>Nagata</surname> <given-names>K</given-names></name><name><surname>Tanokura</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Structure of TTHA1623, a novel metallo-beta-lactamase superfamily protein from <italic>Thermus thermophilus</italic> HB8</article-title><source>Acta Crystallographica Section F Structural Biology and Crystallization Communications</source><volume>65</volume><fpage>455</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.1107/S174430910901361X</pub-id><pub-id pub-id-type="pmid">19407375</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yatsunenko</surname> <given-names>T</given-names></name><name><surname>Rey</surname> <given-names>FE</given-names></name><name><surname>Manary</surname> <given-names>MJ</given-names></name><name><surname>Trehan</surname> <given-names>I</given-names></name><name><surname>Dominguez-Bello</surname> <given-names>MG</given-names></name><name><surname>Contreras</surname> <given-names>M</given-names></name><name><surname>Magris</surname> <given-names>M</given-names></name><name><surname>Hidalgo</surname> <given-names>G</given-names></name><name><surname>Baldassano</surname> <given-names>RN</given-names></name><name><surname>Anokhin</surname> <given-names>AP</given-names></name><name><surname>Heath</surname> <given-names>AC</given-names></name><name><surname>Warner</surname> <given-names>B</given-names></name><name><surname>Reeder</surname> <given-names>J</given-names></name><name><surname>Kuczynski</surname> <given-names>J</given-names></name><name><surname>Caporaso</surname> <given-names>JG</given-names></name><name><surname>Lozupone</surname> <given-names>CA</given-names></name><name><surname>Lauber</surname> <given-names>C</given-names></name><name><surname>Clemente</surname> <given-names>JC</given-names></name><name><surname>Knights</surname> <given-names>D</given-names></name><name><surname>Knight</surname> <given-names>R</given-names></name><name><surname>Gordon</surname> <given-names>JI</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Human gut microbiome viewed across age and geography</article-title><source>Nature</source><volume>486</volume><fpage>222</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1038/nature11053</pub-id><pub-id pub-id-type="pmid">22699611</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zang</surname> <given-names>TM</given-names></name><name><surname>Hollman</surname> <given-names>DA</given-names></name><name><surname>Crawford</surname> <given-names>PA</given-names></name><name><surname>Crowder</surname> <given-names>MW</given-names></name><name><surname>Makaroff</surname> <given-names>CA</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title><italic>Arabidopsis</italic> glyoxalase II contains a zinc/iron binuclear metal center that is essential for substrate binding and catalysis</article-title><source>Journal of Biological Chemistry</source><volume>276</volume><fpage>4788</fpage><lpage>4795</lpage><pub-id pub-id-type="doi">10.1074/jbc.M005090200</pub-id><pub-id pub-id-type="pmid">11085979</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Leon</surname> <given-names>A</given-names></name><name><surname>Song</surname> <given-names>Y</given-names></name><name><surname>Studer</surname> <given-names>D</given-names></name><name><surname>Haase</surname> <given-names>C</given-names></name><name><surname>Koscielski</surname> <given-names>LA</given-names></name><name><surname>Oldfield</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Activity of nitrogen-containing and non-nitrogen-containing bisphosphonates on tumor cell lines</article-title><source>Journal of Medicinal Chemistry</source><volume>49</volume><fpage>5804</fpage><lpage>5814</lpage><pub-id pub-id-type="doi">10.1021/jm060280e</pub-id><pub-id pub-id-type="pmid">16970405</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.66657.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Kana</surname><given-names>Bavesh D</given-names></name><role>Reviewing Editor</role><aff><institution>University of the Witwatersrand</institution><country>South Africa</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2020.12.15.408237">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2020.12.15.408237v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>This submission reports an approach to identify bacterial specific carboxyesterases that can be exploited to activate prodrugs of antibiotics in <italic>Staphylococcus aureus</italic>. The premise is that charged functional groups found in some antibiotics prevent entry of these into bacteria, an effect that can be circumvented through esterification of the antibiotic to allow entry. Thereafter, activation of the antibiotic will occur in the bacterial cytoplasm through hydrolysis by bacterial esterases. The study reports an interesting and generalisable approach to discovery of prodrug-activating enzymes for use in developing new treatments for microbes.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Structure-guided microbial targeting of anti-staphylococcal prodrugs&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by Bavesh Kana as the Senior and Reviewing Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1. The issue of resistance is not addressed sufficiently. This strategy relies on the necessity of non-essential bacterial enzymes for drug activation, which be circumvented by bacteria through mutation of the drug activating enzymes. The dependence on microbial activation is always a liability as has been shown for <italic>M. tuberculosis</italic> agents such as isoniazid and pyrazinamide. Ultimately this can be tested experimentally, for example determining the resistant frequencies for HEX or another prodrug and comparing to frequencies for known antibiotics. This will strengthen the work and provide a more balanced view.</p><p>2. While serum esterase would clearly be a concern, there are also abundant esterases in the liver. No mention was made of stability using liver microsomes or, even better, hepatocytes to get a picture of overall metabolic stability of the leading pro-moieties.</p><p>3. There is little data on the effect of the ether group of the ester on activity, as experiments were done using a fluorescence based system. Some evidence that these selectivities extend to more real-world systems/antibiotics would be helpful</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>Overall, the manuscript is well written and is largely free of typical typographic errors or poorly rendered figures. The writing is clear and logically presented and was overall an enjoyable read. The work conducted appears to be of very high quality and would likely be of wide interest. I am impressed with the overall rigor of the work and have no major issues with the work that has been done. I do have some concerns that should be addressed that relate to the overall applicability and impact of this work.</p><p>(1) A major concern is resistance. This strategy relies on the necessity of non-essential enzymes for drug activation which presents a very simple and obvious mechanism of resistance. In fact, the studies themselves using HEX shows just how easy this can be. The dependence on microbial activation is always a liability as has been shown in <italic>M. tuberculosis</italic> agents such as isoniazid and pyrazinamide. Ultimately this can be tested experimentally, for example determining the resistant frequencies for HEX or another prodrug and comparing to frequencies for known antibiotics.</p><p>(2) While serum esterase would clearly be a concern, there are also abundant esterases in the liver. No mention was made of stability using liver microsomes or, even better, hepatocytes to get a picture of overall metabolic stability of the leading pro-moieties.</p><p>(3) There is little data on the effect of the ether group of the ester on activity as all were done using a fluorescene based system. It would be helpful to see some evidence that these selectivities extend to more real-world systems.</p><p>(4) It would be valuable to give an idea of how many opportunities there are for this and the spectrum of application. How many drug candidates are these for this? Permeability into Gram-positive organisms such as <italic>S. aureus</italic> is usually not much of an issue like it is in Gram-negatives. Outside of a few phosphonates, there aren't many that come to mind. This is also true of organisms, how broad-spectrum would one of these agents be? Perhaps the authors could show the activity of HEX against several pathogens.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>Antimicrobial resistance is a serious problem and S. aureus infections are also still a serious public health threat. The authors presented an interesting approach to the use of prodrugs against <italic>S. aureus</italic> infections. The research paper is very solidly based on scientific results. The research behind this article is very extensive and the basic research presented is very interesting and offers the possibility of developing new antibiotics. I will give more of a perspective as a researcher from antibacterial drug discovery. The advantage of the study is that both crystal structures are also available, allowing structure-based design of antibiotics that could be hydrolyzed by the proposed enzymes.</p><p>– This work lacks a proof-of-concept to confirm the use of the proposed ester groups on real antibiotic molecules and to confirm hydrolysis in <italic>S. aureus</italic> by the two proposed enzymes FrmB and GloB.</p><p>– It is not clear for which functional groups this approach would be most appropriate, hydroxyl, carboxyl?</p><p>– With the introduction of ester groups, the logP is increased and so are inappropriate physicochemical properties. Due to the increased logP, plasma protein binding could be high, thus reducing in vivo efficacy.</p><p>– The last comment refers to the proposed approach for Gram-positive bacteria, where crossing antibiotics through the bacterial cell wall is usually not so problematic. The approach would be much more interesting and necessary for Gram-negative bacteria.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.66657.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1. The issue of resistance is not addressed sufficiently. This strategy relies on the necessity of non-essential bacterial enzymes for drug activation, which be circumvented by bacteria through mutation of the drug activating enzymes. The dependence on microbial activation is always a liability as has been shown for M. tuberculosis agents such as isoniazid and pyrazinamide. Ultimately this can be tested experimentally, for example determining the resistant frequencies for HEX or another prodrug and comparing to frequencies for known antibiotics. This will strengthen the work and provide a more balanced view.</p></disp-quote><p>The reviewers raise an important point regarding the likelihood of resistance based on loss-offunction of GloB and FrmB. Although GloB and FrmB are dispensable in vitro in rich media, this may not be the case in ecological niches (such as infection) where nutrients are more limited and/or additional selective pressures exist. Our findings that GloB and FrmB have extremely high sequence conservation across <italic>S. aureus</italic> isolates (Figure 2 supplement 1) suggests that both proteins have an important biological function that is not immediately evident in rich media. Further, we envision this manuscript as a generalizable approach to discovery of prodrug-activating enzymes for use in developing microbially targeted prodrugs (relatively unexplored in the current literature).</p><p>To experimentally address the reviewers’ concerns, we have also determined the resistance frequency of <italic>S. aureus</italic> Newman to our novel inhibitor, POM-HEX, as well as to clinically relevant antimicrobials including the following: vancomycin, clindamycin, rifampicin, nafcillin, and linezolid at 4x and 10x the MIC of each antibiotic respectively. These new data are included in our manuscript. These results reveal that spontaneous resistance to POM-HEX occurs in rich media somewhat more frequently than rifampicin, and is now included as a new Figure 2, supplement 3 and discussed in the results (lines 166-177).</p><disp-quote content-type="editor-comment"><p>2. While serum esterase would clearly be a concern, there are also abundant esterases in the liver. No mention was made of stability using liver microsomes or, even better, hepatocytes to get a picture of overall metabolic stability of the leading pro-moieties.</p></disp-quote><p>We thank the reviewers for this feedback and agree that evaluating promoiety stability with regards to liver metabolism is also important. Ongoing work in the lab specifically addresses the role of hepatocytes and liver microsomes, to extend our characterization of esterase specificity to multiple cell types and additional pathogens. We have added a section to the discussion to include this important caveat (lines 461-474).</p><disp-quote content-type="editor-comment"><p>3. There is little data on the effect of the ether group of the ester on activity, as experiments were done using a fluorescence based system. Some evidence that these selectivities extend to more real-world systems/antibiotics would be helpful</p></disp-quote><p>As the reviewers point out, our substrate specificity studies specifically address the structure-activity relationship of which prodrug moieties are best recognized by serum and the staphylococcal esterases GloB and FrmB. Our prior work on staphylococcal GloB indicates that GloB homologs de-esterify POM promoieties from structurally diverse antibacterial “warheads” (PMID: 33118347, including the FDA-approved cefditoren pivoxil, see Figure 4 of that manuscript), and our ongoing studies address the degree to which this is true for FrmB and mammalian serum esterases. We believe that our current studies provide novelty in the use of comparative serum vs. microbial esterase specificity to facilitate design of selective esters that may be useful for selective pathogen targeting, irrespective of the warhead.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>Overall, the manuscript is well written and is largely free of typical typographic errors or poorly rendered figures. The writing is clear and logically presented and was overall an enjoyable read. The work conducted appears to be of very high quality and would likely be of wide interest. I am impressed with the overall rigor of the work and have no major issues with the work that has been done. I do have some concerns that should be addressed that relate to the overall applicability and impact of this work.</p><p>1) A major concern is resistance. This strategy relies on the necessity of non-essential enzymes for drug activation which presents a very simple and obvious mechanism of resistance. In fact, the studies themselves using HEX shows just how easy this can be. The dependence on microbial activation is always a liability as has been shown in M. tuberculosis agents such as isoniazid and pyrazinamide. Ultimately this can be tested experimentally, for example determining the resistant frequencies for HEX or another prodrug and comparing to frequencies for known antibiotics.</p></disp-quote><p>We thank the reviewer for their thoughtful and thorough review of our work. We agree that resistance via GloB and FrmB will be a concern for the development of prodrugs utilizing these enzymes for activation. However, while GloB and FrmB are dispensable in vitro in rich media, this may not be the case during an infection setting where nutrients are more limited and additional selective pressures exist. Our finding that GloB and FrmB have extremely high sequence conservation across sequenced <italic>S. aureus</italic> strains (Figure 2 supplement 1) suggests that both proteins have an important biological function that is not uncovered in rich media. Further, we envision this manuscript as a generalizable approach to discovery of prodrug-activating enzymes for use in developing microbially targeted prodrugs. prodrug activation can be targeted (relatively unexplored in the literature currently). With the former in mind, it may prove valuable to unearth essential esterases and perform extensive characterization as we have done here for GloB and FrmB.</p><p>To experimentally address the reviewers’ concerns, we have additionally determined the resistance frequency of <italic>S. aureus</italic> Newman to POM-HEX as well as to clinically relevant antimicrobials including the following: vancomycin, clindamycin, rifampicin, nafcillin, and linezolid at 4x and 10x the MIC of each antibiotic respectively and included these findings in our manuscript. These results reveal that spontaneous resistance to POM-HEX occurs in rich media at somewhat frequency than rifampicin, and is now included as a new Figure 2, supplement 3 and discussed in the results (lines 166-177).</p><disp-quote content-type="editor-comment"><p>2) While serum esterase would clearly be a concern, there are also abundant esterases in the liver. No mention was made of stability using liver microsomes or, even better, hepatocytes to get a picture of overall metabolic stability of the leading pro-moieties.</p></disp-quote><p>We thank the reviewers for this feedback and agree that evaluating promoiety stability in liver systems is critically important. Ongoing work in the lab specifically addresses the role of hepatocytes and liver microsomes, to extend our characterization of esterase specificity to multiple cell types and additional pathogens. We have added a section to the discussion to include this caveat (lines 461-474).</p><disp-quote content-type="editor-comment"><p>3) There is little data on the effect of the ether group of the ester on activity as all were done using a fluorescene based system. It would be helpful to see some evidence that these selectivities extend to more real-world systems.</p></disp-quote><p>We thank the reviewers for this comment. We believe that this work is novel in that it isolates the activity of serum esterases on specific esters and enables one to design selective ester promoieties. We are actively synthesizing prodrugs of HEX (described in manuscript) and another series of phosphonate compounds (fosmidomycin and structural analogs) for additional study in more real-world systems.</p><disp-quote content-type="editor-comment"><p>4) It would be valuable to give an idea of how many opportunities there are for this and the spectrum of application. How many drug candidates are these for this? Permeability into Gram-positive organisms such as <italic>S. aureus</italic> is usually not much of an issue like it is in Gram-negatives. Outside of a few phosphonates, there aren't many that come to mind. This is also true of organisms, how broad-spectrum would one of these agents be? Perhaps the authors could show the activity of HEX against several pathogens.</p></disp-quote><p>We agree with the reviewers that development of novel antibacterials to combat Gram-negative bacteria is also a pressing concern. Creation of prodrugs that successfully mask phosphonate moieties in vivo expands the chemical inhibitor space that can be used to inhibit targets with highly charged active sites (such as many metabolic enzymes). We have previously found that prodrugging improves cellular potency against <italic>P. falciparum</italic> malaria parasites and <italic>Mycobacterium tuberculosis</italic>, both of particular public health concern (PMIDs: 28827774, 27676224). We believe that our studies outline a generalizable approach to addressing improving potency of highly polar compounds through specific prodrugging, which may be useful for those organisms as well. Examples of other anti-infective compounds in development where such prodrugging may be of use include the following references: PMIDs 31567411, 33361818, 31483651, 30730737, and reviewed in 31469328.</p><p>Our previously published studies give a strong indication as to the antimicrobial spectrum of prodrugs modified with lipophilic esters like POM, as we have previously characterized the activity of a series of analogs that target the 2-C-methyl-D-erythritol 4-phosphate pathway for isoprenoid biosynthesis. Similar to HEX, these “MEPicide” compounds possess a phosphonate warhead that requires active transit to pass the cell membrane. Non-prodrug (parent) analogs of these inhibitors readily engage and inhibit the highly conserved antimicrobial target enzyme (DXR) from multiple organisms in vitro and therefore have a broad antimicrobial spectrum. However, POM-prodrug variants of these MEPicides have markedly reduced antibacterial efficacy against many Gram-negative organisms (PMID: 32497104). Tested organisms included the following: Escherichia coli, Klebsiella pneumoniae, Salmonella typhimurium, Shigella sonnei, Serratia marcescens, and Burkholderia thailandensis. Notable exceptions are Francisella novicida and Mycobacterium tuberculosis (PMIDs: 23077474, 22024034). These previously published findings are echoed in our preliminary studies of POM-HEX (outside the scope of this current manuscript that focuses on S. aureus), in which we find that POM-HEX and POM-SF are much more potent against S. aureus than HEX or SF, but the reverse is true for <italic>E. coli</italic>. We believe that either POM-containing prodrugs are excluded from most Gram-negatives or they are not activated by their intracellular esterases, and in response to the reviewers’ concern, we now include these hypotheses in the discussion (lines 478 – 485).</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>Antimicrobial resistance is a serious problem and S. aureus infections are also still a serious public health threat. The authors presented an interesting approach to the use of prodrugs against <italic>S. aureus</italic> infections. The research paper is very solidly based on scientific results. The research behind this article is very extensive and the basic research presented is very interesting and offers the possibility of developing new antibiotics. I will give more of a perspective as a researcher from antibacterial drug discovery. The advantage of the study is that both crystal structures are also available, allowing structure-based design of antibiotics that could be hydrolyzed by the proposed enzymes.</p><p>– This work lacks a proof-of-concept to confirm the use of the proposed ester groups on real antibiotic molecules and to confirm hydrolysis in <italic>S. aureus</italic> by the two proposed enzymes FrmB and GloB.</p></disp-quote><p>We thank the reviewers for this comment. We believe that this work is novel in that it isolates the activity of serum esterases on specific esters and enables one to design selective esters. We are actively synthesizing prodrugs of HEX (described in manuscript) and another series of phosphonate compounds (fosmidomycin and structural analogs) for additional study in more real-world systems.</p><disp-quote content-type="editor-comment"><p>– It is not clear for which functional groups this approach would be most appropriate, hydroxyl, carboxyl?</p></disp-quote><p>To date we have primarily investigated phosphate and phosphonate antibiotics where attachment of a promoiety to the phosph(on)ate oxygen(s) is beneficial. We hypothesize that this is due to occlusion of the charge, which facilitates transit across the Gram-positive membrane (PMID: 32497104) Ultimately, the limitations to this approach may be determined by the route of chemical synthesis used for the inhibitors in question.</p><disp-quote content-type="editor-comment"><p>– With the introduction of ester groups, the logP is increased and so are inappropriate physicochemical properties. Due to the increased logP, plasma protein binding could be high, thus reducing in vivo efficacy.</p></disp-quote><p>We agree with the reviewer that lipophilic ester prodrugging strategies require attention to logP, although many successful anti-infectives and anti-parasitics do not follow’s Lipinski’s Rules as closely as other therapeutics (see commentary by McKerrow and Lipinski, PMID: 28623818). However, small molecule substrate-mimetic phosphonates (e.g., fosmidomycin, PubChem CID 572; and SF2312, PubChem CID 52913330) have excellent engagement of their protein targets in vitro but poor drug-like properties (logP &lt; -2); in such cases, lipophilic ester prodrugging may improve both bioavailability, cellular permeability, and PK, thus improving in vivo efficacy. In fact, POM prodrugging has been successfully used for a number of FDA-approved antimicrobials, including cefditoren pivoxyl, sulbactam pivoxil, and adefovir dipivoxil.</p><disp-quote content-type="editor-comment"><p>– The last comment refers to the proposed approach for Gram-positive bacteria, where crossing antibiotics through the bacterial cell wall is usually not so problematic. The approach would be much more interesting and necessary for Gram-negative bacteria.</p></disp-quote><p>We agree with the reviewers that development of novel antibacterials to combat Gram-negative bacteria is also a pressing concern. Creation of prodrugs that successfully mask phosphonate moieties in vivo expands the chemical inhibitor space that can be used to inhibit targets with highly charged active sites (such as many metabolic enzymes). We have previously found that prodrugging improves cellular potency against <italic>P. falciparum</italic> malaria parasites and <italic>Mycobacterium tuberculosis</italic>, both of particular public health concern (PMIDs: 28827774, 27676224). We believe that our studies outline a generalizable approach to addressing improving potency of highly polar compounds through specific prodrugging, which may be useful for those organisms as well. Examples of other anti-infective compounds in development where such prodrugging may be of use include the following references: PMIDs 31567411, 33361818, 31483651, 30730737, and reviewed in 31469328.</p><p>Our previously published studies give a strong indication as to the antimicrobial spectrum of prodrugs modified with lipophilic esters like POM, as we have previously characterized the activity of a series of analogs that target the 2-C-methyl-D-erythritol 4-phosphate pathway for isoprenoid biosynthesis. Similar to HEX, these “MEPicide” compounds possess a phosphonate warhead that requires active transit to pass the cell membrane. Non-prodrug (parent) analogs of these inhibitors readily engage and inhibit the highly conserved antimicrobial target enzyme (DXR) from multiple organisms in vitro and therefore have a broad antimicrobial spectrum. POM-prodrug variants of these MEPicides have markedly reduced antibacterial efficacy against many Gram-negative organisms (PMID: 32497104), including Escherichia coli, Klebsiella pneumoniae, Salmonella typhimurium, Shigella sonnei, Serratia marcescens, and Burkholderia thailandensis. However, POM-prodrugging is effective in improving cellular potency against Francisella novicida and Mycobacterium tuberculosis (PMIDs: 23077474, 22024034). These previously published findings are echoed in our preliminary studies of POM-HEX (outside the scope of this current manuscript that focuses on S. aureus), in which we find that POM-HEX and POM-SF are much more potent against S. aureus than HEX or SF, but the reverse is true for <italic>E. coli</italic>. We believe that either POM-containing prodrugs are excluded from most Gramnegatives or they are not activated by their intracellular esterases, and in response to the reviewers’ concern, we now include these hypotheses in the discussion (lines 478 – 485).</p></body></sub-article></article>